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Thesis abstract  
BACKGROUND: Long-term exposure to organophosphates (OPs) can cause chronic neurotoxic effects 
which may be modulated by genetic polymorphisms of xenobiotic metabolising enzymes (XMEs). No 
previous study investigated XME modulation of neurotoxicity outcomes. 
 
OBJECTIVES: To investigate whether XMEs polymorphisms modulate OP neurotoxicity among emerging 
farmers.  
 
METHODS: A cross-sectional study of 301 emerging farmers was conducted in the rural Western Cape of 
South Africa. Neurotoxicity testing included the World Health Organisation Core Test Battery (digit span 
forward and backward) and vibration sensitivity testing. Questionnaire items included demographic data, 
potential confounders and work history of pesticide exposures. Blood samples were analysed for genetic 
polymorphisms of the following XMEs; glutathione S-transferases (GST), N-acetyltransferases (NAT) and 
Paraoxonase (PON1). 
 
RESULTS: Median age was 39 (30-48) and most had 9 years of education or less (65.5%). 54% of the 
participants were OP pesticide applicators. There was a low prevalence of the GST null genotype (GSTT-
1% and GSTM-16%) and the GA and GG genotype for NAT (10%). Modulation of OP exposure and 
neurotoxic outcome relationships by NAT, PON1 at position 192 and GST was indicated in multivariate 
analysis. The strongest evidence of modification was by NAT on the relationship between pesticide 
poisoning and impaired vibration sense. Poisoned individuals with the GG genotype were more likely to 
suffer from impaired vibration sense compared to GA and AA genotypes.  
 
CONCLUSION: Genetic polymorphisms of NAT, PON1 (at position 192) and GSTM may modify the 
relationship between OP exposure and neurotoxicity. Larger longitudinal studies are required to 
determine whether preventive strategies can be developed to improve health amongst the identified 
vulnerable groups.  
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1. Literature Review  
1.1. Introduction 
 
Globally, organophosphates (OPs) are currently among the most widely used class of pesticides (Costa et 
al. 2005; Mackness et al. 1997; Singh et al. 2011a). OPs were previously used as nerve agents in chemical 
warfare and for crop protection in agriculture. OP pesticide-related chemical derivatives are also used as 
pharmaceutical agents for the treatment of glaucoma and schistosomiasis and for mosquito control in the 
prevention of transmission of malaria (Costa et al. 2003a).  
 
Exposure to OP pesticides is associated with negative effects on the central nervous system (CNS). This is 
because OPs inhibit acetylcholinesterase (AChE), an enzyme that inactivates the neurotransmitter, 
acetylcholine. The inhibition of AChE results in the accumulation of acetylcholine which causes the over 
stimulation of postsynaptic cholinergic receptors and disrupts the transmission of neuron impulses at 
nerve endings (Alavanja et al. 2004; Costa et al. 2003b). Neurotoxic effects associated with OP exposure 
in humans vary with the duration and the quantity of the chemical that the individual is exposed to. Acute 
high dose OP exposure is associated with dizziness, increased salivation, nausea, vomiting and in more 
severe cases, respiratory difficulty and seizures. Long-term low-dose exposure to OPs can cause 
generalised weakness, tremors and a decrease in cognitive functions, such as impairment in memory and 
concentration. The harmful effects are less clear for low level, long term OP exposure, largely due to the 
difficulties associated with exposure measurement (Costa et al. 2005). 
 
In addition to the acute symptoms described earlier, OP exposure has been linked to a wide range of 
adverse health outcomes including neurodegenerative diseases such as Parkinson's disease and 
Alzheimer's disease (Baldi et al. 2003; Freire and Koifman 2012; Le Couteur et al. 1999), cancers such as 
Non-Hodgkin’s lymphoma, leukemia and multiple myeloma (Mills and Zahm 2001), respiratory problems 
and asthma (Faria et al. 2005; Hoppin et al. 2008; Hoppin et al. 2009) and depression and anxiety 
(Mackenzie Ross et al. 2010). Previous studies have also found an association between prenatal maternal 
OP pesticide exposure and neurodevelopmental deficits in early childhood, in addition to low birth weight 
and birth length (Bouchard et al. 2011; Engel et al. 2007; Eskenazi et al. 2007; Grandjean et al. 2006; 
Whyatt et al. 2004; Young et al. 2005). 
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1.2. Neurotoxic effects due to long-term organophosphate pesticide exposure 
 
1.2.1. OP pesticides and neurobehavioural performance 
 
A number of epidemiological studies have investigated the effects of OP pesticides on neurobehavioural 
performance. The tests for neurobehavioural performance used in these studies include the World Health 
Organization Neurobehavioral Core Test Battery (WHO NCTB), the Q16 questionnaire and the Behavioural 
Assessment and Research System (BARS). A few studies found that OP exposure decreased 
neurobehavioural performance in adults including workers who were exposed to OPs through sheep 
dipping (Stephens et al. 1995), workers in greenhouses (Bazylewicz-Walczak et al. 1999), applicators and 
non-applicators on crop farms (Rohlman et al. 2007; Kamel et al. 2003).  
However, some studies found a positive association between OP exposure and neurobehavioural 
performance while others found no association (Holtman 2013; London et al. 1997; Major 2010; Rodnitzky 
1975). The results from studies investigating the effects of long-term OP pesticide exposure on 
neurobehavioural performance, are therefore inconsistent among adults. 
 
1.2.2. OP pesticides and vibration sensitivity  
 
Vibration sensitivity testing is frequently used in epidemiologic studies to determine the toxic effects of 
OPs (Holtman 2013; London et al. 1998; Pilkington et al. 2001; Steenland et al. 1994; Stokes et al. 1995). 
The test is used to assess an individual’s peripheral somatosensory function. As with studies that assessed 
the effect of OP on neurobehavioural performance, inconsistent findings were reported for the studies 
investigating the association between OP exposure and vibration sensitivity (Holtman 2013; Lee et al. 
2003; London et al. 1998). 
A study found that farmers exposed to OPs exhibited a non-significant higher mean vibration threshold 
sensitivity for both the dominant and non-dominant hands compared to the non-exposed individuals 
(Stokes et al. 1995). Various tests were performed in the study done by Steenland et al. (1994), including 
neurobehavioural, nerve conducting and vibrotactile sensitivity tests. The results showed that the OP 
poisoned cases performed significantly worse on vibrotactile sensitivity tests than those not poisoned. 
Other studies have also shown a decrease in vibration sensitivity among those exposed compared to non-
exposed (Cole et al. 1997; Holtman 2013; McConnell et al. 1994).  
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1.3. The effect of genetic polymorphisms of OP pesticide metabolizing enzymes on 
neurotoxicity 
 
Evidence has emerged, largely from animal studies, that certain enzymes are capable of detoxifying 
metabolites of OPs and therefore reducing the risk of harmful outcomes (Costa et al. 1998). Furthermore, 
genetic polymorphisms or variations of these xenobiotic metabolising enzymes (XMEs) exist in human 
populations, thereby accounting for variability in metabolising properties among individuals. Paraoxonase 
(PON1), Glutathione S-transferases (GST) and N-acetyltransferases (NAT) are some of the studied XMEs 
(Costa et al. 2003a; Costa et al. 2003b; Singh et al. 2011a; Singh et al. 2011b; Singh  et al. 2012).  
 
1.3.1. PON1 enzyme 
 
Paraoxonase (PON1) is a calcium-dependent enzyme responsible for hydrolysing the metabolites of 
several OPs. PON1 is produced in the liver and secreted into the plasma. The enzyme belongs to a family 
of proteins which includes PON2 and PON3. Unlike PON1, PON2 and PON3 do not have the ability to 
metabolise OPs (Costa et al. 2003a).  
In addition to hydrolysing OPs, PON1 is capable of metabolising a range of lactones and oxidised lipids 
including both low density and high density lipoproteins (HDL). Because of its multiple biological roles, 
PON1 plays a role in the pathophysiology of many diseases (Costa et al. 2013).  
 
1.3.1.1. Polymorphisms of the PON1 gene 
 
Genetic studies have shown that PON1 expression varies in the human population (Costa et al. 2005; 
Eckerson et al. 1983), where PON1 gene activity has been observed to vary between 10-40 fold and PON1 
plasma levels may vary up to 13 fold between individuals (Davies et al. 1996; Humbert et al. 1993). Studies 
have shown that environmental factors, genetic polymorphisms and other factors such as age, sex and 
nutrition can all affect the levels of PON1 in plasma. However, genetic polymorphisms have been shown 
to have the biggest effect on variability of PON1 function (Costa et al. 2003b; Ferré et al. 2003; Vincent-
Viry et al. 2003).  
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Two polymorphisms affect the functional activity of PON1, namely, the glutamine (GLN or Q)/arginine 
(ARG or R) substitution at position 192 (PON1-192Q/R) and the leucine (LEU or L) /methionine (MET or M) 
substitution at position 55 (PON1-55L/M) (Costa et al. 2003b; Costa et al. 2005). The polymorphism at 
position 55 is responsible for PON1 levels in plasma and the polymorphism at position 192 determines 
catalytic efficiency. LEU has been associated with higher PON1 plasma levels when compared to MET at 
this position.  At position 192, the ARG alloform hydrolyses paraoxon more rapidly than GLN. In contrast, 
GLN hydrolyses OPs; diazinon, sarin and soman at a more rapid rate than ARG does (Costa et al. 2005; 
Costa et al. 2013). 
 
 
1.3.1.2. Evidence from animal studies for the effect of PON1 on OP neurotoxicity  
 
Animal studies have supported the hypothesis that PON1 may modify the neurotoxic effects of OP 
pesticides. Experiments where PON1 serum from rabbits were injected into rats showed that rats who 
received PON1 and a dose of OPs had significantly less neurotoxic deficits compared to those injected 
with OPs only (Costa et al. 2003c). Furthermore, a number of studies involving rabbits, rats, mice and birds 
have shown different degrees of neurotoxic effects in animals with known differences in PON1 levels 
(Costa et al. 1998).  
 
 
1.3.1.3. Epidemiological studies investigating the effect of PON1 polymorphisms on OP 
neurotoxicity amongst workers exposed to pesticides 
 
 
Four studies that investigated the effect of PON1 on OP toxicity amongst workers exposed to pesticides 
were identified in the literature (Lee et al. 2003; Mackness et al. 2003; Singh et al. 2011b; Sozmen et al. 
2002). These studies, although conducted in different settings, using different study designs and 
investigating different health outcomes, provide evidence that the susceptibility to the toxic effects of 
OPs vary among individuals and that the variation is due to the PON1 polymorphism at positions 55 and 
192 of the PON1 gene.  
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A cross-sectional study conducted on farmers in the Western Cape province of South Africa found that 
farm workers with the GLN/GLN homozygous (Q192Q/Q) or GLN /ARG (Q192R) heterozygote genotypes 
were almost three times more (OD=2.80; CI: 1.7 – 6.9) likely to report symptoms associated with chronic 
OP poisoning compared to those with the homozygous ARG/ARG (R192R) genotype at position 192. 
Furthermore, the prevalence of chronic OP poisoning was the lowest among the non-applicators with the 
homozygous R192R genotype followed by the non-applicators with the Q192Q or Q192R and the 
applicators with the R192R genotype. The prevalence of OP poisoning was the highest among the 
applicators with the Q192R or Q192Q genotype (Lee et al. 2003).  
 
 
A case-control study by Mackness et al. (2003) in the UK was done to determine the association between 
PON1 polymorphism and reported chronic ill health, among sheep dipping farmers who were 
occupationally exposed to OPs particularly, diazoxon. Based on the literature, the Q-contaning alloenzyme 
hydrolyses diazoxon more rapidly than the R alloenzyme. From the study, more controls had the Q 
alloenzyme than the cases (60.6% vs 39.7%), showing that individuals with the Q192Q and Q192R amino 
acid combination were 2.39 (95% CI = 1.46 – 3.98) times more likely to be a ‘case’ than those with the 
R192R amino acid combination. Furthermore, individuals with the L55L amino acid combination were 3.16 
(95% CI=1.88 – 5.31) times more likely to be a case than those with the L55M and/or M55M amino acid 
combination.  
 
Sozmen et al. (2002) investigated cases who were poisoned through oral ingestion, injection and with the 
intention of suicide in Turkey. The study found that PON1 activity was lower in the cases when compared 
to the controls, (30% lower activity: 114.2 nmol/mL/min vs 152.9 nmol/mL/min) and six months later upon 
remeasurement, the PON1 levels of the cases increased. Furthermore, cases were more likely to have the 
Q192 alloenzyme of PON1 polymorphism than controls. Individuals with the Q192 (likelihood ratio = 
7.637, P=0.022) and M55 (likelihood ratio=4.721, P=0.094) alloenzymes were more sensitive to OP toxicity 
than other groups. Lastly, PON1 is an important determinant of OP sensitivity as individuals with mild 
symptoms of OP poisoning had higher PON1 activity than participants who experienced severe symptoms 
(Sozmen et al. 2002). 
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Singh et al. (2011b) conducted a study in India, investigating the effect of PON1 polymorphism on 
genotoxicity in the form of DNA damage. Exposed participants sprayed OPs for public health programmes 
and the controls were healthy volunteers. The study found that for both the exposed and control group, 
the R192R genotype had the higher PON1 activity compared to the Q192Q genotype. Similarly, the L55L 
genotype showed higher PON1 activity than the M55M genotype. Furthermore, participants with the 
Q192/Q and M55M genotype had a higher prevalence of DNA damage and were therefore more 
susceptible to the effects of OPs (Singh et al. 2011b). 
 
1.3.2. Genetic polymorphisms of other xenobiotic metabolizing enzymes  
 
In addition to PON1, Glutathione S-transferases (GST) and N-acetyltransferases (NAT) are XMEs capable 
of detoxifying OPs (Abhishek et al. 2010; Abel et al. 2004). Four epidemiologic studies have investigated 
the effect of these XMEs on OP toxicity. Three of the studies were done in India, where DNA damage 
among OP pesticide workers was investigated (Singh et al. 2011a; Singh et al. 2012). The first study found 
that DNA damage was significantly higher among workers exposed to OPs (14.37±2.15) compared to 
controls (6.24± 1.37) and DNA damage was higher among participants with the GSTM1 null genotype 
compared to those with the GSTM1 positive genotype (15.18 vs. 14.15 tail % DNA, p = 0.03). Furthermore, 
there was no effect of the GSTT1 null genotype on DNA damage (Singh et al. 2011a). The second study 
found that DNA damage was higher among those with the GSTM1 null genotype and the NAT2 slow 
acetylators. In addition, mild to severe smokers with the NAT2 slow acetylators were also shown to be 
more sensitive to the effects of OPs through increased DNA damage (Singh et al. 2012).  
  
 
A similar study was conducted by Abhishek et al. (2014) in India, investigating the effect of GST (GSTT1 
and GSTM1) enzymes on DNA damage among individuals occupationally exposed to pesticides. The study 
showed that GSTT1 played an important role in OP susceptibility but GSTM1 had no effect on DNA 
damage. Individuals with the GSTT1 null genotype showed greater levels of DNA damage compared to 
those with the GSTT1 positive genotype (14.43 vs 9.82, p-value<0.05).  
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Lastly, the study by Godoy et al. (2014) in Brazil looked at GST polymorphisms (GSTT1 and GSTM1) and 
pesticide toxicity in individuals who were occupationally exposed to pesticides. Among the participants, 
18% had the GSTT1 null genotype, 49% had the GSTM1 null genotype and 10% had both null genotypes. 
The study found no association between the GST (GSTT1 and GSTM1) polymorphisms and pesticide 
toxicity. Furthermore, the authors identified personal protection equipment (PPE) as an important 
determinant in pesticide intoxication.  
 
2. Problem statement 
 
 
OP pesticide exposure has been associated with acute and chronic neurotoxicity.  XMEs such as GST, NAT 
and PON1 have been shown to detoxify OPs. Laboratory studies have shown that genetic variations exist 
in these enzymes, causing a variation in their activity in human populations. It is therefore, understandable 
that some individuals may be more susceptible to the adverse health effects of OPs (Costa et al. 2003a; 
Costa et al. 2005).  
 
 
In the literature, no epidemiological studies investigating the effect of XME genetic polymorphisms on 
long-term OP neurotoxicity could be identified. The few epidemiological studies that have been conducted 
have focused on outcomes such as DNA damage and acute pesticide intoxication. Furthermore, these 
studies showed differing results. Singh et al. (2011a) found that the genetic polymorphism of GSTM1 
modified OP DNA damage whereas Abhishek et al. (2014) found that GSTT1 played an important role in 
DNA damage resulting from OP exposure. A few studies have also indicated that PON1 polymorphism 
modifies OP pesticide toxicity and DNA damage (Lee et al. 2003; Mackness et al. 2003; Singh et al. 2011b; 
Sozmen et al. 2002). Despite the widespread use of OP pesticides in South African agriculture, only one 
study was previously conducted in the country (Lee et al. 2003).   
 
 
The effect of genetic polymorphisms of XMEs on long-term OP neurotoxicity in human population is 
therefore largely unstudied. 
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3. Research aim and objectives  
 
3.1. Aim 
 
The aim of this study is to determine whether genetic polymorphisms of XMEs (GST: GSTM1 and GSTT1, 
NAT2 and PON1: at positions 55 and 192) modify the neurotoxic effects (neurobehavoural performance 
and vibration sensitivity) of occupational OP pesticide exposure among emerging farmers and 
farmworkers in the Western Cape of South Africa.  
 
3.1.1. Objectives  
 
 To describe the demographic and socio-economic profile of emerging farmers in the Western 
Cape  
 To determine the long-term exposure to OP pesticides among the emerging farmers and 
farmworkers 
 To measure chronic neurotoxic outcomes among the emerging farmers through the use of 
neurobehavioural tests and vibration sense testing 
 To determine the relationship between long-term exposure to OPs and performance on 
neurobehavioural tests and vibration sense testing, among emerging farmers and farmworkers 
 To determine the prevalence of genetic polymorphisms of XMEs (GST: GSTM1 and GSTT1, NAT2 
and PON1: at positions 55 and 192) among emerging farmers and farmworkers 
 To determine the effect of XMEs genetic polymorphisms on the relationship between long-term 
exposure to OPs and performance on neurobehavioural tests and vibration sense testing, 
controlling for confounders. 
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3.2. Hypothesis  
 
The hypothesis of this study is that genetic polymorphisms of XMEs modifies the neurotoxicity of OP 
pesticides among emerging farm workers.   
 
4. Methods 
4.1. Study Design, Sampling and Study Population 
 
This cross-sectional study forms part of a larger cohort study investigating the relationship between long-
term OP pesticide exposure and neurobehavioural deficits among emerging farmers and farmworkers 
(Holtman 2013). This study used the baseline data collected by Holtman (2013), to investigate the effect 
of XMEs genetic polymorphisms on OP neurotoxicity. 
 
The participants were selected from farmer projects registered with the Land Reform Office in South 
Africa. In 2009 in the Western Cape, 183 emerging farmer projects were registered encompassing a total 
of 14 624 emergent farmers. Due to ease of accessibility, the study sample was restricted to projects from 
the following districts: Overberg, Cape Winelands and the West Coast. The farmer projects in these three 
selected districts were considered to be a representative sample of the projects in the Western Cape 
(Holtman 2013). Deciduous fruit, vegetables, grapes, cotton, flowers and livestock were produced on the 
farms. 
 
Of the 63 projects registered in the selected districts, 34 were eligible to participate in the study based on 
the inclusion/exclusion criteria. Twenty-one farmer projects were approached and agreed to participate 
in the study. Therefore, 62% of the eligible projects were represented in the study sample.  
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A total of 326 farmers from the projects who agreed to participate in this study were eligible for inclusion, 
of whom 316 (97%) agreed to participate. The farmers were interviewed for their demographic 
information, lifestyle information such as smoking and alcohol consumption, medical history and work 
information. Blood samples were taken at the beginning of the study to determine genetic variations of 
the XMEs.  
 
4.2. Inclusion and exclusion criteria 
 
The criteria for inclusion in the study were the following: 
 Farms using pesticides 
 Farms in one of the three districts (Cape Winelands, Overberg and West Coast) 
 Emerging farmers or adult family members 
 Males and females 18 years and older 
 
The criteria for exclusion from the study were the following: 
 Organic or farms that did not use pesticides or in the process of switching to methods that did not 
include pesticides 
 Hired labourers 
 Adults with an abnormality of the lower limbs were excluded from vibration sense testing 
 Individuals with a history of the following medical conditions: 
- Encephalitis 
- Tuberculosis Meningitis 
- Stroke, Organic brain syndrome 
 Individuals with a history of use of psychotropic medication 
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4.3. Sample Size Calculation 
 
The sample size calculation was based on the means and variances sourced from studies that assessed 
neurobehavioural performance of individuals occupationally exposed to OPs (Cole et al. 1997; Kamel et 
al. 2003; London et al. 1997). Using a significance level of 5% and power of 80%, it was calculated that a 
sample of 160-350 participants were needed to identify anticipated differences in neurobehavioural tests.   
 
Table 1: Studies assessing neurobehavioural performance of OP occupational exposure 
Neurobehavioural 
outcomes  
Reference 
study 
Exposed group 
mean (SD) 
Non-exposed 
group mean 
(SD) 
Based on comparing 
cumulative exposure: 50% 
prevalence (cumulative 
exposure cut off at 
median (1:1) 
Based on comparing acute 
episodic exposures over 
12 months: 10% incidence 
(1:9) 
Digit Span 
Cole et al. 1997 6.8 (2.0) 7.5 (2.4) 314   75 (n1) 
(157 + 157) 675 
(n2)
  
Total  N = 314 750 
Kamel et al. 
2003 
4.74 (0.99) 5.63 (1.02) 42   11 (n1) 
(21 + 21)   99 (n2) 
Total  N = 42 110 
London et al. 
1997 
4.8 (1.0) 5.2 (1.0) 198   55 (n1) 
(99 + 99) 495 (n2) 
Total  N = 198 550 
 
Heed pilot 2005 
 
8.7 (3.05) 
 
7.00 (3.07) 
 
244 
   
29 (n1) 
(122 + 122) 261 (n2) 
Total  N = 244 290 
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Neurobehavioural 
outcomes  
Reference 
study 
Exposed group 
mean (SD) 
Non-exposed 
group mean 
(SD) 
Based on comparing 
cumulative exposure: 50% 
prevalence (cumulative 
exposure cut off at 
median (1:1) 
Based on comparing acute 
episodic exposures over 
12 months: 10% incidence 
(1:9) 
Digit Symbol 
Srivasta et al. 
2000 
51.0 (10.9) 62.4 (13.7) 38  9 (n1) 
(19 + 19) 81(n2) 
Total  N = 38 90 
Heed pilot 2005 17.5 (9.1) 13.4 (9.1) 156   43 (n1) 
(78 + 78) 387 (n2) 
Total  N = 156 430 
London et al. 
1997 
25.3 (10.4) 20.9 (9.5) 162   48 (n1) 
(81 +81) 432 (n2) 
Total  N = 162 480 
Cole et al. 1997 25.0 (12.4) 22.3 (7.5) 454 196 (n1) 
(227 + 227) 392 (n2)        
Total  N = 454 588 
Santa Ana 
Kamel et al. 
2003 
18 (3.49) 19.9 (3.04) 94 37 (n1) 
(47 + 47) 74 (n2)        
Total  N = 94 111 
London et al. 
1997 
38.5 (6.9) 35.9 (7.7) 250   90 (n1) 
(125 + 125) 180 (n2)        
Total  N = 250 270 
Heed pilot 2005 36 (8.7) 31 (9.3) 102 38 (n1) 
(51 + 51) 76 (n2)        
Total  N = 102 114 
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Neurobehavioural 
outcomes  
Reference 
study 
Exposed group 
mean (SD) 
Non-exposed 
group mean 
(SD) 
Based on comparing 
cumulative exposure: 50% 
prevalence (cumulative 
exposure cut off at 
median (1:1) 
Based on comparing acute 
episodic exposures over 
12 months: 10% incidence 
(1:9) 
Benton Visual 
 
Cole et al. 1997 
 
8.7 (2.7) 
 
9.8 (2.2) 
 
158 
  
63 (n1) 
(79 +79) 126 (n2)        
Total  N = 158 189 
London et al. 
1997 
6.9 (2.0) 6.1 (2.1) 208   77 (n1) 
(104 +104) 154 (n2)        
Total  N = 208 231 
Heed pilot 2005 5.35 (2.58) 4.62 (1.70) 282 120 (n1) 
(141 +141) 240 (n2)        
Total  N = 282 360 
 
4.4. Measurement Instruments 
 
4.4.1. Questionnaire 
 
Trained interviewers administered a questionnaire titled the Farmer Questionnaire (see Appendix A) to 
participants in their spoken language (English and Afrikaans). These questionnaires were back-translated 
in these languages. The questionnaires included sections on demographic data such as age, sex and 
education level; information about potential confounders such as alcohol use, smoking, previous head 
injuries and information regarding current and previous work related exposures to pesticides. Information 
about previous pesticide poisoning was also collected. The Farmer Questionnaire was successfully piloted 
in the three districts before the study was conducted.  
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To determine occupational exposure to pesticides, the details of the number of years and number of days 
performing applicator (mixing, tractor boom spraying, hand-spraying) and non-applicator activities for the 
current and 4 previous jobs were obtained from the questionnaires (Appendix A). Details of the pesticides 
used in these jobs were also obtained to determine if OP pesticides were applied. Additionally, the crops 
produced on the farms were identified to determine the crop-sector in which a particular job was 
performed. The total number of days worked in all these jobs was calculated and weighted by job activity 
using Job-exposure matrices (JEMs). JEMs have been shown to be a repeatable proxy for exposure to 
pesticides in the Western Cape (London and Myers 1998). The JEM weighted days was further weighted 
by crop sector to obtain JEM crop weighted days. Exposure intensity was determined by dividing these 
JEM weighted days and JEM crop weighted days by the number of years worked. These exposure indices 
were determined for all pesticide exposure as well as OP specific exposures.  
 
4.4.2. Testing for neurotoxicity 
 
In the main study, neurotoxicity was assessed using tests from the WHO Neurobehavioral Core Test 
Battery (WHO NCTB) and vibration sensitivity testing. The WHO NCTB tests are pen and paper-based tests 
that are administered orally. These tests are therefore easily administered and have been shown to 
consistently identify neurotoxicity among individuals who had been occupationally exposed to pesticides. 
Furthermore, London et al. (1997) have shown that these tests are successfully administered to individuals 
with low education levels.  
 
Vibration sensitivity threshold test was conducted as studies have shown that OP exposure is associated 
with impaired vibration sensitivity (Steenland et al. 1994; Stokes et al. 1995). These tests were conducted 
by trained research assistants in the main study. In this thesis, the results of the Digit Span tests and 
Vibration tests will be analysed. 
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4.4.2.1. Digit Span tests 
  
The Digit Span forward and backward WHO NCTB tests assesses the participants’ verbal memory and 
involves an administrator reading out a sequence of numbers to the participant, who then repeats the 
sequence to the administrator. The aim of the test is to repeat the sequence in the correct order. Initially 
the administrator reads out a sequence consisting of three numbers and as the test continues, more 
numbers are added to the sequence, increasing the complexity of the test. 
 
In the Digit Span forward test, the participants are required to repeat the sequence of numbers in the 
same order as read by the administrator, and evaluates the participant’s attention. The Digit Span 
backward test requires the participant to repeat the sequence of numbers, read by the administrator, in 
the reverse order. The backward test therefore tests the participant’s memory.  
 
For both of the tests, a score of one is given for each sequence correctly repeated. For example, a score 
of 2 is awarded if the participant repeated both sequences, forward and backward, correctly. In contrast, 
a score of 0 is awarded when both sequences are incorrectly repeated. Depending on the sequence of 
numbers, it is possible for an individual to achieve a total score ranging between 0 and 28. Furthermore, 
the digit span Wechsler Adult Intelligence Scale (WAIS) results will also be included in this study. The digit 
span WAIS score is the combined score for digit span forward and backward, adjusted for the participant’s 
age and gender.  
 
4.4.2.2. Vibration Sense Threshold  
 
Vibration sensitivity will be measured using a 256-Hz frequency tuning fork on the participant’s non-
dominant lower limb, while they are seated.  After applying the tuning fork, the participant was asked 
whether he/she felt the vibration sensation and to inform the examiner when the vibration sensation was 
no longer felt. Three readings will be recorded and the average reading of the last two will be used as the 
final extinction time for each participant. 
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4.4.3. Genetic Polymorphism 
 
A qualified nurse drew 10 ml whole blood sample from all participants in the field which was kept at room 
temperature and then transported to the UCT Human Genetics laboratory on the same day. The 
genotyping for XMEs; PON1 (at the position 92 and 55), GSTT1, GSTM1 and NAT2 (single nucleotide) was 
done. 
The Puregene® DNA Purification Kit was used to isolate DNA from peripheral blood lymphocytes (Gentra 
Systems, Minneapolis, USA).  The concentration and quality of DNA was assessed by spectrophotometry 
and agarose gel electrophoresis respectively.  
 
4.5. Statistical analysis 
 
The variables used in the statistical analysis are depicted in Table 2 below. 
 
Table 2: List of variables 
  
Variable Name Type 
DEMOGRAPHIC INFORMATION 
Gender Binary (Male/Female) 
Age Continuous (Years) 
Language 
Categorical (English/Afrikaans/ 
IsiXhosa/IsiZulu) 
Education Binary (High:>9 years/Low:≤9 years) 
Type of crop farming 
Categorical (Any combination/ 
Citrus/Deciduous/Grapes/No 
crops/Other/Vegetables) 
Height Continuous (Metres) 
Weight Continuous (Kilograms) 
BMI Continuous 
Alcohol Consumption Binary (Yes/No) 
Smoking status Binary (Yes/No) 
Head Injury Binary (Yes/No) 
Psychiatric Illness Binary (Yes/No) 
PESTICIDE EXPOSURE 
Pesticide Applicators (all pesticides and OP 
pesticide) 
Binary (Yes/No) 
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Variable Name Type 
Days worked unweighted by activity or crop 
sector (all pesticides and OP pesticide) 
Continuous (Days) 
Days worked weighted by JEM (JEM days) 
for all pesticides and OP specific pesticides 
Continuous (Days) 
 Days worked weighted by JEM and crop 
sector (JEM crop days) both for all 
pesticides and OP specific pesticides 
Continuous (Days) 
Intensity of exposure: JEM days and JEM 
crop days divided by number of years 
worked  
Continuous (Days) 
JEM days (weighted by JEM) for all 
pesticides and OP specific pesticides 
Categorical (non-exposed/≤25th 
percentile/≤50th percentile/≤75th 
percentile/≥75th percentile) 
Diagnoses of past pesticide poisoning Binary ((Yes/No) 
XENOBIOTIC METABOLISING 
ENZYMES 
GSTT1 Binary (Null/Yes) 
GSTM1 Binary (Null/Yes) 
NAT2 Categorical (GG/GA/AA) 
PON1_55 Categorical (TT/TA/AA) 
PON1_192 Categorical (GG/GA/AA) 
NEUROBEHAVIOURAL OUTCOMES 
Digit Span Forward Continuous (Test score) 
Digit Span WAIS Continuous (Test score) 
Vibration Sensitivity Continuous (Test score) 
Digit Span Forward 
Categorical (High:≥median/Low: 
≤median) 
Digit Span WAIS 
Categorical (High:≥median/Low: 
≤median)  
Vibration Sensitivity 
Categorical (High:≥median/Low: 
≤median) 
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From the above, there are eleven exposure variables, three outcome variables and five effect 
modifiers, the XMEs (GSTT1, GSTM1, NAT2, PON1_55 and PON1_192)  
 
4.5.1. Exploratory data analysis  
 
To describe the sample population exploratory data analysis, univariate and multivariate (mostly 
bivariate) analysis will be done. For the univariate analysis, histograms to determine the distribution 
and summary statistics will be calculated for the continuous variables.  The categorical variables will 
be explored using frequency tables. Furthermore, box-plots will be created to identify any outliers in 
the data. Associations between two continuous variables will be explored through scatter plots and 
box plots will be created to explore associations between continuous and categorical variables. 
Contingency tables will be used to identify associations between two categorical variables.  
 
Either the two-tailed t-test for normally distributed continuous variables or the Wilcoxon rank sum 
test for continuous non-normal variables will be used to compare the means of continuous variables. 
The Fisher exact test or the chi-squared test will be used to determine the bivariate associations 
between categorical variables.  
 
4.5.2. Multivariate Analysis  
 
All statistical analysis will be performed using the statistical software package STATA 13 (StataCorp. 
2013. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP). Linear and logistic 
multiple regression analysis will be used to determine the relationship between pesticide exposure 
and neurobehavioural outcomes. Two sets of models will be created for each outcome, exposure and 
genetic variable combination. The first set of models will show the relationship between OP exposure 
and neurobehavioural outcomes adjusted for confounders and the second set of models will include 
the gene-exposure interaction term. Confounders will be identified from literature and variables 
found to have significant (p  0.05) association with neurobehavioural outcomes in the bivariate 
analysis. Models showing significant interactions will be stratified by polymorphism categories.  
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5. Ethics 
 
This cross-sectional study is a sub-study of the study titled Neurobehavioural effects of pesticide 
exposure among emerging farmers in the Western Cape by Holtman (2013), which has received ethical 
approval by the Research Ethics Committee, Health Sciences Faculty of the University of Cape Town 
(REC REF: 477/2007). The purpose of the study was clearly explained to potential participants, verbally 
and in their predominant language. A study information sheet (see Appendix B) was used and this was 
done before consent to participate was obtained. Written informed consent (see Appendix C) was 
obtained in accordance with the requirements of the Helsinki Declaration and the Medical Research 
Council of South Africa guidelines (World Medical Association (WMA) 2000; South African Medical 
Research Council (MRC) 1993). Consent forms were provided in English and Afrikaans.  
 
Furthermore, safety training with materials developed by the Centre for Environmental and 
Occupational Health Research Unit (CEOHR), UCT were provided to participants as a form of 
compensation. Any participants who were identified with neuropsychological disorders or any 
untreated injuries were referred to local health care providers.  
 
Anonymity was achieved through the use of study numbers rather than participants’ names. 
Furthermore, confidentiality was maintained as the research team only had access to the data and 
group results were reported. 
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 PART B: Structured Literature Review   
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1. Introduction 
 
1.1. Background and Objectives of literature review 
 
Worldwide organophosphate (OP) pesticides, first synthesised in the 1940’s, are the most widely used 
chemical class of pesticides (Costa et al. 2005a; Mackness et al. 1997; Singh et al. 2011a). The OP 
pesticides are used for pest control in various sectors such as agriculture, horticulture and in domestic 
and commercial settings. South Africa is the largest consumer of pesticides in sub-Saharan Africa and 
in the Western Cape Province the production of fruit and wine are important for export and therefore, 
for economic growth (Naidoo and Buckley 2003).  
 
OPs have been associated with a wide range of negative health effects including neurodegenerative 
diseases such as Parkinson's and Alzheimer's disease (Baldi et al. 2003; Le Couteur et al. 1999; Freire 
and Koifman 2012), cancers such as Non-Hodgkin’s lymphoma, leukemia and multiple myeloma (Mills 
and Zahm 2001), respiratory problems and asthma (Faria et al. 2005; Hoppin et al. 2008; Hoppin et al. 
2009) and depression and anxiety (Mackenzie Ross et al. 2010).  
 
There is evidence that xenobiotic metabolising enzymes (XMEs) such as Glutathione S-transferases 
(GST), N-acetyltransferases (NAT2) and Paraoxonase (PON1) are capable of detoxifying metabolites of 
OPs (Costa et al. 2003a; Singh et al. 2011a; Singh et al. 2012). Furthermore, the evidence indicates 
that among humans, the activity of these enzymes are determined by genetic polymorphisms. 
Therefore, susceptibility to the harmful effects of OPs may vary in human populations (Costa et al. 
1999; Costa et al. 2003a; Costa et al. 2005a; Singh et al. 2011b; Singh et al. 2012; Lee et al. 2003; 
Mackenzie Ross et al. 2010).   
 
The objectives of this literature review were to: i) provide an overview of the neurotoxic effects of OP 
pesticides, ii) review studies investigating the neurotoxic effects associated with long-term OP 
pesticide exposure in humans, iii) identify genetic polymorphisms of XMEs that modify OP 
neurotoxicity in human populations and iv) review epidemiological studies investigating the effect of 
XMEs genetic polymorphisms on OP neurotoxicity.    
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1.2. Search strategy  
 
For the first two objectives, the most recent reviews and textbooks were consulted.  
For objectives 3 and 4, the following search strategy was used: literature published between 1975 
and September 2015 were searched for using the electronic search tools: PubMED 
(http://www.ncbi.nlm.nih.gov/pubmed/), MEDLINE 
(https://www.nlm.nih.gov/bsd/pmresources.html) and Google Scholar 
(https://www.google.co.za/webhp?sourceid=chrominstant&ion=1&espv=2&ie=UTF-
8#q=google%20scholar). References of the identified articles were checked for any unidentified 
literature and relevant articles suggested by these search engines were also considered. 
Furthermore, only laboratory and epidemiological studies investigating genetic polymorphisms of 
the following XMEs were included in the review: glutathione S-transferases (GSTT1 and GSTM1), N-
acetyltransferases (NAT2) and Paraoxonase (PON1).  
 
For the epidemiological studies, studies on all populations exposed to OP pesticides including: men, 
women or children and farm and non-farm populations were included in the review. Studies from all 
developing and developed countries that were available, and all study designs were included in the 
review.  
 
1.3. Search terms 
 
Search terms for objective 1 and 2 included: 
Pesticide, organophosphate, organophosphorous, OP, neurotoxic, neurobehavioural, 
neurobehavioral and health effects of pesticides 
Search terms for objective 3 and 4 included: 
Genetic polymorphism, OP pesticides, Paraoxonase, PON, PON1, Glutathione S-transferases, GST, N-
acetyltransferases, NAT, xenobiotic metabolising enzymes and genetic susceptibility. 
 
  
28 
 
2. Neurotoxicity of organophosphate pesticides 
 
OP pesticides are neurotoxic, capable of affecting the central and peripheral nervous system (Costa et 
al. 2005). Depending on the level of exposure, OPs can result in four distinct neurological syndromes: 
(1) acute cholinergic effects, (2) Intermediate Syndrome (IMS), (3) Organophoshorous-induced 
delayed neurotoxicity (OPIDN) and lastly, (4) organophosphorus ester-induced chronic neurotoxicity 
(OPICN).   
 
2.1. Acute cholinergic effects 
 
Acute cholinergic effects including salivation, sweating, muscle twitching, reduced consciousness, 
bronchial secretion and constriction of the bronchi, arise after an acute single dose of exposure to 
OPs. In extreme instances acute cholinergic effects can manifest as seizures and respiratory failure 
due to paralysis of the diaphragm. These symptoms may arise as soon as a few hours, or as late as five 
days after exposure, and it is possible to recover from these adverse cholinergic effects (Costa et al. 
2003c; Major 2010).  
 
The symptoms of this syndrome arise due to the accumulation of the neurontransmitter, acetylcholine 
at the nerve endings. Exposure to OPs inhibit acetylcholinesterase (AChE), an enzyme that inactivates 
acetylcholine. The inhibition of AChE causes an accumulation of acetylcholine which results in the over 
stimulation of postsynaptic cholinergic receptors and the disruption of the transmission of neuron 
impulses, thus leading to the common cholinergic effects (Alavanja et al. 2004; Costa et al. 2005a).  
 
2.2. Intermediate syndrome (IMS) 
 
IMS is characterised by weakness of the neck and eye muscles, proximal skeletal and respiratory 
muscles which may last for as long as 6 weeks. The syndrome occurs 1-4 days following acute OP 
intoxication and after the acute cholinergic effects. Between 20%-50% of poisoned cases result in IMS. 
The mechanism that causes IMS is not yet well known, but individuals with this type of neurotoxicity 
can recover from the symptoms within 3 weeks (Balali-Mood and Saber 2012; Major 2010). 
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2.3. Organophoshorous induced delayed neurotoxicity (OPIDN) 
 
The OPIDN toxicity occurs after IMS, 4 weeks after either a large single dose of OPs or repeated 
exposures to OPs. The syndrome is characterised by general muscle weakness and pain including initial 
paraesthesia and calf pain, weakness in the distal leg muscles resulting in foot drop, and claw hand 
caused by weakening of the muscles in the hands (Costa et al. 2005a; Major 2010).  
 
Recovery from OPIDN can take as long as 12 months and may not be complete. Although the 
mechanism of this syndrome is unclear it is thought that it occurs due to the phosphorylation of 
neuropathy target esterase (NTE) (Costa et al. 2003a; Lotti and Moretto 1999).  
 
2.4. Organophosphorus ester-induced chronic neurotoxicity (OPICN) 
 
OPICN is characterised by neurobehavioural, neurological and neuropsychological symptoms caused 
by exposure to either a large single dose of OP or long-term repeated low OP exposure. Symptoms 
therefore include cognitive dysfunction, difficulty concentrating, tremors, lack of motor control, 
generalized weakness, impairment of visual memory, a decrease in verbal attention, anxiety and 
depression. Unlike the other syndromes, the effects of OPICN can continue years after the OP 
exposure (Stallones and Beseler 2002; Savage et al. 1988). 
Neurotoxicity due to long-term OP pesticide exposure includes effects on neurobehavioral 
performance and effects on vibration sense (Holtman 2013). 
 
2.5. Neurobehavioural performance and long-term exposure to OP pesticides 
 
A recent review included several studies that investigated the association between long-term OP 
pesticide occupational exposure and neurobehavioural performance, and found that the findings of 
these have not been consistent (Ismail et al. 2012). For instance, a cross-sectional study in south-
eastern Spain showed that exposure to OPs leads to lower neuropsychological performance among 
pesticide applicators.  
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The applicators performed worse on the Benton Visual Form Recognition Tests (OR=6.93, 95% CI: 
1.52– 31.51), when compared to the reference group. This test assesses visual perception and memory 
(Roldán-Tapia et al. 2005). Another cross-sectional study done on adolescents occupationally exposed 
to OPs found that the applicators performed significantly worse on neurobehavioural tests of memory 
and attention span compared to the non-applicators (Rohlman et al. 2014). However, a cohort study 
done found that occupational exposure to the OP pesticide, chlorpyrifos, had no effect on peripheral 
neuropathy and no association with nerve conduction study (NCS) (Albers et al. 2004).  
 
The lack of accurate exposure measurement, small sample sizes, differences in neurobehavioural 
measurement and study designs have been described as the causes for the inconsistent results 
produced (Ismail et al. 2012).   
 
Three meta-analysis were conducted to determine the effects of long-term OP exposure. The first was 
done by Ismail et al. (2012) on 17 studies and the second done by Ross et al. (2013) on 14 studies between 
the years 1960 and 2012. The more recent study was done by Meyer-Baron et al. (2015) on 22 eligible 
studies, between 1965 and 2010. Individuals were generally exposed through OP pesticide application 
and manufacturing. These meta-analyses showed that OP exposed individuals performed worse on 
attention and memory tests compared to the non-exposed group.   
 
Furthermore, reviews by Colosio et al. (2009) and Rohlman et al. (2011) also found that the majority 
of the studies showed an association between OP exposure and neurobehavioural deficit among 
individuals occupationally exposed.  
 
These reviews also showed that studies that focused on the neurobehavioural effects associated with 
OP poisoning have produced consistent results (Colosio et al. 2009). For instance, a cross sectional 
study on farmers in China who had been poisoned in the last 12 months, showed that participants 
performed significantly worse on WHONCTB (digit span forward and backward, digit symbol, Benton 
visual retention, correct pursuit aiming and error pursuit aiming scores) compared to non-poisoned 
individuals (Zhang et al. 2016). A study conducted in Florida, on individuals occupationally exposed to 
OPs for at least 1 month, showed that OPs negatively impacted performance on digit span (OR = 1.90; 
CI 1.02-3.53), tapping (coefficient = 4.13; 95% CI, 0.00-8.27), Santa Ana test (coefficient = 1.34; 95% 
CI, 0.29-2.39) and postural sway (coefficient = 4.74; 95% CI, -2.20 to 11.7) tests (Kamel et al. 2003).  
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Three studies investigating the effects of cumulative exposure to OP pesticides and neurobehavioural 
performance have been conducted in South Africa, all of which were in the Western Cape Province 
(Holtman 2013; London et al. 1997; Major 2010). All the studies found no association between OP 
exposure and neurobehavioural performance. The comparison group in these studies were farm 
workers who may have been exposed to OPs.  London et al. (1997) focused on deciduous fruit farm 
workers, Major (2010) on grape farmers and Holtman (2013) on emerging farmers in the Western 
Cape Province. Two of the three studies were cross sectional studies. Major (2010) used the general 
health questionnaire (GHQ) and the Brief Symptom Inventory (BSI) to determine neurotoxic outcomes 
associated with OP exposure, but found no association among the 817 South African fruit farmers. 
London et al. (1997) found a very small association between Pursuit-Aiming and Santa Ana tests, but 
no association with the 5 other tests from the WHO Neurobehavioral Core Test Battery (WHO NCTB). 
 
The only cohort study in SA was conducted by Holtman (2013) on 319 emerging farmers. 
Neurobehavioural performance was assessed using a combination of tests from the WHO NCTB, Brief 
symptom inventory (BSI) and the Swedish Q16. The study found no significant association between 
long-term OP exposure and neurobehavioural performance, but found that individuals that 
experienced pesticide poisoning in the past performed worse on the digit span forward test, which 
tests memory and attention (OR 2.67; 95% CI 1.05 - 6.80).  
 
2.5.1. OP pesticides and vibration sensitivity 
 
Few studies have investigated the effect of OP exposure on peripheral somatosensory function, 
decreased vibration sensitivity. A review of studies investigating the association between OP exposed 
workers and vibration sensitivity have shown inconsistent results (Holtman 2013). OP applicators in 
the Agricultural Health Study (AHS) showed decreased toe vibration sensitivity compared to non-
applicators (Starks et al. 2012). A study done by Steenland et al. (1994) also found associations 
between OP exposure and decreased vibration sense. A cross-sectional study in Eucador found that 
applicators had a lower toe vibration threshold compared to the control group (Cole et al. 1997).  
However, Stokes et al. (1995) found a non-significant higher mean vibration threshold sensitivity for 
both the dominant and non-dominant hands compared to the general population.  
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Three studies have been conducted in South Africa. Two have found significant impairment in 
vibration sensitivity among the exposed group (Holtman 2013; London et al. 1998). Manjra et al. (ND) 
found a decrease in vibration sense among the OP applicators and Holtman (2013) found impaired 
vibration sense among emerging farmers. However, London et al. (1998) found no association 
between OP exposure and impaired vibration sensitivity among fruit farmers in the Western Cape 
Province.  
 
3. Genetic polymorphism of XMEs 
 
3.1. Glutathione S-transferases (GST) 
 
GST, which are also present in plants and bacteria, have been shown to play an important role in insect 
resistance to insecticides including OPs (Clark 1989; Fournier et al. 1992; Reidy et al. 1990; Wei et al. 
2001).  In humans, there are four distinct classes of GST including, alpha (A), mu (M), pi (P) and theta 
(T) and these are distributed to different tissues. In human populations, the polymorphism of the Mu 
(GSTM1) and Theta (GSTT1) classes are well documented. The polymorphisms occur due to gene 
deletions resulting in null genotypes. The Individuals with the null genotypes are suspected to be more 
sensitive to effects of OPs due to its reduced metabolising properties (Abel et al. 2004).   
 
3.2. N-acetyltransferases (NAT2) 
 
The two N-acetyltransferases that are polymorphic in human populations are called NAT1 and NAT2. 
These enzymes are involved in the detoxification of a variety of aromatic amine and hydrazine drugs. 
The enzyme NAT2 was discovered before NAT1, and the NAT2 polymorphism was identified when the 
differences in isoniazid toxicity among TB patients was noted. In addition to detoxifying various drugs, 
N-acetyltransferases are carcinogen and OP metabolising enzymes, and due to their polymorphic 
distribution in humans, it is postulated that some individuals may be more susceptible to the harmful 
effects of these exposures than others. Several epidemiologic studies have linked variants in NAT2 to 
urinary, bladder, colorectal, breast and lung cancer (Grant et al. 1997; Hein et al. 2000; Hein 2002).  
 
33 
 
3.3. Paraoxonase (PON1) 
 
Paraoxonase (PON1) is a calcium-dependent enzyme responsible for hydrolysing the metabolites of 
several OPs and a range of lactones and oxidised lipids (HDL and LDL) (Costa et al. 2013). The enzyme 
is named ‘paraoxonase’ because it hydrolyses paraoxon which is the active metabolite of parathion, 
one of the most studied OPs (Costa et al. 2013). In humans, PON1 is produced in the liver and secreted 
into the plasma. The enzyme belongs to a family of proteins which also includes PON2 and PON3. 
Unlike PON1, PON2 and PON3 do not metabolise OPs (Costa et al. 2005a).  
 
Laboratory studies have shown that PON1 activity in the human population (Costa et al. 2005a; 
Eckerson et al. 1983) vary between 10-40 fold (Humbert et al. 1993) and PON1 plasma levels may vary 
up to 13 fold between individuals (Davies et al. 1996). The variability occurs due to environmental 
factors such as age, sex and nutrition, and due to polymorphisms on the PON1 gene.  Genetic 
polymorphisms have been found to have the biggest effect on variability of enzyme levels between 
individuals (Ferré et al. 2003; Vincent-Viry et al. 2003).  
 
Animal studies have shown that PON1 may modify the neurotoxic effects of OP pesticides (Costa et 
al. 1999; Costa et al. 2003b). A number of studies involving rabbits, rats, mice and birds have shown 
different degrees of neurotoxic effects in animals with known differences in PON1 levels (Costa et al. 
1999). Further evidence from an experiment where PON1 serum from rabbits were injected into rats, 
showed that rats who received PON1 and a dose of OPs had significantly less neurotoxic deficits 
compared to those injected with OPs only (Costa et al. 2003a). 
 
Two polymorphisms affect the activity of PON1, the glutamine (GLU)/arginine (ARG) substitution at 
position 192 (PON1-192Q/R) and the leucine (LEU)/methionine (MET) substitution at position 55 
(PON1-55L/M). The LEU/MET ploymorphism is responsible for PON1 levels in plasma and the 
GLU/ARG polymorphism determines catalytic efficiency. Leucine has been associated with higher 
PON1 plasma levels when compared to methionine, but the efficiency of the GLU/ARG polymorphism 
is substrate specific. Arginine has been shown to hydrolyse paraoxon more rapidly, while glutamine 
metabolises diazinon, sarin and soman at a more rapid rate (Costa et al. 2005a; Furlong et al. 2005). 
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3.4. Effect of XME polymorphisms on OP toxicity 
 
Table 1 summarises epidemiological studies that have investigated the effect of XMEs (GST: GSTT1 
and GSTT1, NAT2 and PON1: PON1-55 and PON1-192) polymorphisms on OP pesticide neurotoxicity 
and DNA damage. There were four studies investigating PON1 polymorphism and four investigating 
the GST and NAT2 polymorphisms. 
 
 
3.5. Epidemiological studies investigating the effect of PON1 polymorphisms 
on OP neurotoxicity 
 
 
A cross-sectional study conducted on farmers in the Western Cape Province of South Africa found that 
subjects with the PON1-192Q/Q or PON1-192Q/R genotypes were almost three times more likely to 
report symptoms that were associated with chronic OP poisoning compared to those with the PON1-
192R/R genotype (CI: 1.7 – 6.9). Furthermore, the prevalence of chronic OP poisoning appeared to be 
the lowest among the non-applicators with the PON1-192R/R genotype, followed by the non-
applicators with the PON1-192Q/Q and the PON1-192Q/R genotype. The prevalence of OP poisoning 
was the highest among the applicators with the PON1-192Q/Q or the PON1-192Q/R genotypes (Lee 
et al. 2003). 
 
 
A case-control study by Mackness et al. (2003) was conducted to determine the association between 
PON1 polymorphisms and reported chronic ill health among sheep dipping farmers. These farmers 
were from the United Kingdom and occupationally exposed to OPs, particularly diazoxon. From the 
literature the 192Q alloenzyme hydrolyses diazoxon more rapidly than the R alloenzyme and in this 
study, more controls had the Q alloenzyme than the cases (60.6% vs 39.7%). The results showed that 
individuals with the PON1-192 QQ and the PON1-192 QR genotype were 2.39 (95% CI = 1.46 – 3.98) 
times more likely to be a case than those with the PON1-192 RR genotype. Furthermore, individuals 
with the PON1-192 LL genotype were 3.16 (95% CI=1.88 – 5.31) times more likely to be a case than 
those with the PON1-192 MM polymorphism.  
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A study done in Turkey by Sozmen et al. (2002) investigated the effect of OP poisoning on PON1. Cases 
were poisoned through oral ingestion, injection and with the intention of suicide. The study found 
that PON1 activity was lower in the cases when compared to the controls, (30% lower activity: 114.2 
nmol/mL/min vs 152.9 nmol/mL/min). Six months later, when measured again, the PON1 levels of the 
cases increased. Furthermore, cases were more likely to have the Q alloenzyme for PON1 
polymorphism at position 192 than controls. Individuals with the Q (likelihood ratio = 7.637, P=0.022) 
and M (likelihood ratio=4.721, P=0.094) alloenzymes for polymorphisms at position 192 and 55 
respectively, were more sensitive to OP intoxication than other groups. PON1 is an important 
determinant of OP sensitivity as individuals with mild symptoms of OP poisoning had higher PON1 
activity than participants who experienced severe symptoms.  
 
 
Lastly, a cross sectional study conducted in New Delhi, India by Singh et al. (2011b) investigated the 
effect of PON1 polymorphism on genotoxicity in the form of DNA damage. Exposed participants 
sprayed OPs for public health programmes and the controls were healthy volunteers. The study found 
that for both the exposed and control group, the individuals with the PON1-192 RR genotype had the 
higher PON1 activity compared to those with the PON1-192 QQ polymorphism. Similarly, the 
participants with the PON1-55 polymorphism showed higher PON1 activity than those with the PON1-
55 MM genotype. Furthermore, participants with the PON1-192 QQ and PON1-55 MM genotypes had 
a higher prevalence of DNA damage and were therefore more susceptible to the effects of OPs.   
 
Although all studies provided evidence that PON1 polymorphisms modify OP toxicity, the study by 
Mackness et al. (2003) found the PON1-192 RR and the PON1-55 LL genetic variants to be the ‘slow’ 
metabolisers, which is in contrast to the other studies.  The three earlier studies (Lee et al. 2003; 
Mackness et al. 2003; Sozmen et al. 2002) investigated poisoning as a health outcome and not chronic 
neurotoxicity; and Singh et al. (2011b) focused on DNA damage. There is, therefore, no data from 
epidemiological studies on the effect of PON1 polymorphism on OP chronic neurotoxicity. 
Furthermore, no cohort studies were conducted and the exposure variables were categorical 
(applicator status). Cohort studies using more sensitive outcome of chronic neurotoxicity and 
exposure measurements are therefore required. 
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3.6. Epidemiological studies investigating the effect of GST and NAT 
polymorphisms on OP neurotoxicity 
 
In addition to PON1, GST (GSTM1 and GSTT1) and NAT2 are XMEs capable of detoxifying OPs (Abhishek 
et al. 2010; Godoy et al. 2014; Singh et al. 2012). Four epidemiologic studies have investigated the 
effect of these XMEs on OP toxicity. Two of the studies were done by Singh et al., who investigated 
DNA damage among OP pesticide workers (Singh et al. 2011a; Singh et al. 2012). The first study found 
that DNA damage was significantly higher among workers exposed to OPs (14.37±2.15) compared to 
controls (6.24± 1.37) and DNA damage was higher among participants with the GSTM1 null genotype 
compared to those with the GSTM1 positive genotype (15.18 vs. 14.15 tail % DNA, p = 0.03). 
Furthermore, there was no effect of the GSTT1 null genotype on DNA damage and OP exposure (Singh 
et al. 2011a). The second study found that DNA damage was higher among those with the GSTM1 null 
genotype and in NAT2 slow acetylators. Furthermore, mild to severe smokers who were NAT2 slow 
acetylator, were also shown to be more sensitive to the effects of OPs, through increased DNA damage 
(Singh et al. 2012).  
  
 
A similar study was conducted by Abhishek et al. (2014) in India, investigating the effect of GST (GSTT1 
and GSTM1) enzymes on DNA damage among individuals occupationally exposed to pesticides. The 
study showed that GSTT1 played an important role in OP susceptibility, but that GSTM1 had no effect 
on DNA damage. The individuals with the GSTT1 null genotype showed higher DNA damage compared 
to those with the GSTT1 positive genotype (14.43 vs 9.82, p-value<0.05).  
 
 
Lastly, the study by Godoy et al. (2014) in Brazil looked at pesticide intoxication and GST 
polymorphisms (GSTT1 and GSTM1). Participants were occupationally exposed to pesticides. Among 
the participants, 18% had the GSTT1 null genotype, 49% the GSTM1 null genotype and 10% had both 
null genotypes. The study found no association between the GSTT1 and GSTM1 polymorphisms and 
pesticide intoxication. Instead personal protection equipment (PPE) was reported to be an important 
determinant in pesticide intoxication (Godoy et al. 2014).  
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Only one of the studies investigated the effect of GST polymorphisms on OP toxicity, but found no 
evidence of effect modification (Godoy et al. 2014).  The remaining studies showed that GST played a 
significant role in OP toxicity modification, but DNA damage was investigated as a health outcome and 
not chronic neurotoxicity. There is therefore little data from epidemiological studies on the effect of 
GST and NAT2 polymorphisms on OP chronic neurotoxicity. 
 
In addition to few studies been conducted, the findings of the existing studies are inconsistent. This 
could be due to chance, differences in study designs or due to different measurement of the exposure. 
Furthermore, the studies were conducted in different settings, the differences in genetic background 
could therefore have also contributed to the difference in findings.  
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Table 3: Summary of epidemiological studies investigating the effect of XMEs genetic polymorphisms on OP 
neurotoxicity AND genotoxicity 
Author, year Population 
(n), Study 
design and 
Setting 
OP exposure assessment Outcome variable Genotype assessment Findings 
Studies investigating PON1 polymorphism 
Sozmen et al. 2002 Case control 
study of 94 
subjects (28 OP 
poisoned 
patients and 66 
healthy 
volunteers) 
Izmir Turkey.  
Patients admitted to emergency 
service at Ataturk Research and 
Educational Hospital in October 
1999 – July 2000. Route of OP 
poisoning included oral (n=26), 
injection (n=1) and inhalation 
(n=1). 
Acute OP intoxication PON1 at position 192 The study found that PON1 activity was lower 
in the cases when compared to the controls, 
(30% lower activity: 114.2 nmol/mL/min vs 
152.9 nmol/mL/min) and six months later, the 
PON1 levels of the cases increased. 
Furthermore, cases were more likely to have 
the Q alloenzyme for PON1 polymorphism at 
position 192 than controls. Individuals with the 
Q (likelihood ratio = 7.637, P=0.022) and M 
(likelihood ratio=4.721, P=0.094) alloenzymes 
for polymorphisms at position 192 and 55 
respectively, were more sensitive to OP 
intoxication than other groups. 
Lee et al. 2003 A cross 
sectional study 
of 100 farm 
workers from 
Western Cape 
Province, South 
Africa.  
Applicator status.(applicator vs 
non-applicator) Subjects were 
matched by characteristics such 
as age. 
OP chronic toxicity (subjects 
with two or more symptoms 
associated with OP chronic 
toxicity, self-reported) 
PON1 at position 192 Having one of the either Gln/Gln or Gln/Arg 
genotypes independently predicted an 
increased risk of neurotoxic symptoms (OR 2.9, 
95% CI 1.7-6.9).  Furthermore, the prevalence 
of chronic toxicity increased in a stepwise 
fashion from 15.0% among pesticide non 
applicators with a “fast metabolism” (Arg/Arg) 
genotype, to 42.9% among pesticide non 
applicators with “slow metabolism” (Gln/Gln 
or Gln/Arg) genotypes, to 58.8% among 
pesticide applicators with “fast metabolism” 
genotype, and 75.0% among pesticide 
applicators with “slow metabolism” genotypes 
(P=0.001).  
Mackness et al. 2003 A case control 
study of 396 
sheep dippers in 
the UK. 
OP exposure while sheep dipping  Self-reporting of chronic ill 
health. 
PON1 at positions 192 and 55. Cases were found to be more likely to have the 
R192 allele and the L55 allele when compared 
to the controls. A combination of the R 
(position 192) and the L (position 55) 
genotypes was associated with lower PON1 
activity towards diazoxon in both cases and 
controls. 
Singh et al., 2011b This cross 
sectional study 
consisted of 230 
participants. 
The study took 
place in New 
Delhi, India.  
The number of hours applying 
OP pesticides in all jobs was 
determined for all participants. 
Those with more than 2400 h 
were classified as exposed. 
DNA damage (Tail moment) 
as a proxy for genotoxicity. 
DNA damage was evaluated 
using the alkaline comet 
assay. 
The PON1 genotypes at position 
192 were determined by PCR 
amplification using previously 
described primers. 
The results revealed that PON1 activity toward 
paraoxon was significantly lower in workers 
than in control subjects (179.19±39.36 vs. 
241.52±42.32 nmol/min/ml). The DNA damage 
was observed to be significantly higher in 
workers than in control subjects and the 
individuals with PON1 Q/Q and M/M 
genotypes (slow genes) showed significantly 
higher DNA damage compared to other 
isoforms  
(pb0.05). 
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Author, year Population 
(n), Study 
design and 
Setting 
OP exposure assessment Outcome variable Genotype assessment Findings 
Studies investigating GST and NAT2 polymorphisms 
Singh et al. 2011a A cross-
sectional study 
with 230 
participants 
conducted in 
New Delhi, 
India.  
An index was calculated for each 
interviewed subject (based on 
their 
hours/day×days/year×years). 
Subjects with an exposure index 
of more than 2400 h were 
classified as exposed. The non-
exposed group had less than 
2400 h OP exposure. 
DNA damage (Tail moment) as 
a proxy for genotoxicity. DNA 
damage was evaluated using 
the alkaline comet assay. 
An individual multiplex PCR 
(polymerase chain reaction) was 
carried out to determine GST 
genotyping. Globin gene was 
used as an internal control 
The first study found that DNA damage was 
significantly higher among workers exposed to 
OPs (14.37±2.15) compared to controls (6.24± 
1.37) and DNA damage was higher among 
participants with the GSTM1 null genotype 
compared to those with the GSTM1 positive 
genotype (15.18 vs. 14.15 tail % DNA, p = 
0.03). There was no effect of the GSTT null 
genotype on DNA damage 
Singh et al. 2012 A cross-
sectional study 
of 230 
participants 
conducted in 
New Delhi, 
India.  
An index was calculated for each 
interviewed subject (based on 
their 
hours/day×days/year×years). 
Subjects with an exposure index 
of more than 2400 h were 
classified as exposed.  
DNA damage (Tail moment) as 
a proxy for genotoxicity. DNA 
damage was evaluated using 
the alkaline comet assay. 
An individual multiplex PCR 
(polymerase chain reaction) was 
carried out to determine GST 
genotyping. Globin gene was 
used as an internal control 
The second study found that DNA damage was 
higher among those with the GSTM null 
genotype and the NAT slow acetylators. 
Furthermore, mild to severe smokers with the 
NAT2 slow acetylators were also shown to be 
more sensitive to the effects of OPs, through 
the increased DNA damage (Singh et al, 2012). 
Abhishek et al. 2014 A cross-
sectional study 
of 67 
participants 
conducted in 
Punjab, India 
The exposed group consisted of 
40 workers exposed to various 
pesticides and a group of 27 
unexposed control agricultural 
workers with an average age of 
36.1 and 38.4 years, 
respectively. 
Damage Index (DI) and 
Damage Frequency (DF), were 
used to measure DNA 
damage. They were 
determined by summing up 
the visual score of 100 cells of 
each individual. 
Furthermore, % DNA in tail 
was also used to measured 
DNA damage. % DNA in tail 
was measured using the 
computerized image analysis 
software 
(TriTek CometScore). 
Genotyping of the GST enzymes 
was done using multiplex PCR 
described 
by Arand et al. 1996 
DNA damage was significantly more prevalent 
among the exposed group compared to the 
unexposed. Furthermore, Individuals with the 
GSTT1 null genotype showed greater levels of 
DNA damage compared to those with the 
GSTT1 positive genotype (% DNA tail 14.43 vs 
9.82, p-value<0.05). 
Godoy et al. 2014 A cross-
sectional study 
of 235 farm 
workers, from 
the Goias 
municipalities 
Brazil.  
Applicator status (Applied/ not 
applied pesticides) 
Number of events of OP 
intoxication 
GSTT (The quantitative 
polymerase chain reaction 
(qPCR) method was used) 
Found no association between GSTT1 and 
GSTM1 null polymorphisms and intoxicated 
events. Found an association between PPE and 
events of intoxication and therefore presents 
the importance of PPE use.   
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4. Conclusion 
 
There is consistent evidence in international literature that a history of OP pesticide poisoning causes 
neurotoxicity among farm workers but inconsistent evidence that long-term pesticide exposure, 
controlling for pesticide poisoning, causes neurotoxicity (Holtman 2013). Only three studies have been 
conducted in South Africa, one of them a cohort study with one year of follow-up (Holtman 2013; 
London et al. 1997; Major 2010). Furthermore, none of these studies found an association between 
long-term OP exposure and neurobehavioural performance. 
 
Few cross-sectional and case control have investigated the effect XMEs genetic polymorphisms on 
health outcomes associated with long-term OP pesticide exposure (Lee et al. 2003; Sozmen et al. 2002; 
Singh et al. 2011a; Singh et al. 2011b; Singh et al. 2012). The studies that have been conducted provide 
some evidence that the genetic polymorphisms of XMEs may modify OP toxicity. However, the types 
of effect in these studies are inconsistent. Exposure indices in these studies were not sensitive and 
none investigated neurotoxic outcomes apart from poisoning and DNA damage.  
 
Future research requires more cohort studies investigating the effect of XMEs polymorphisms on 
long-term OP pesticide exposure neurotoxicity. Furthermore, these future studies should use more 
sensitive OP exposure measurements and outcome instruments in different settings, including South 
Africa.  
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Thesis abstract  
Thesis abstract  
BACKGROUND: Long-term exposure to organophosphates (OPs) can cause chronic neurotoxic 
effects which may be modulated by genetic polymorphisms of xenobiotic metabolising enzymes 
(XMEs). No previous study investigated XME modulation of neurotoxicity outcomes. 
 
OBJECTIVES: To investigate whether XMEs polymorphisms modulate OP neurotoxicity among 
emerging farmers.  
 
METHODS: A cross-sectional study of 301 emerging farmers was conducted in the rural Western Cape 
of South Africa. Neurotoxicity testing included the World Health Organisation Core Test Battery (digit 
span forward and backward) and vibration sensitivity testing. Questionnaire items included 
demographic data, potential confounders and work history of pesticide exposures. Blood samples 
were analysed for genetic polymorphisms of the following XMEs; glutathione S-transferases (GST), N-
acetyltransferases (NAT) and Paraoxonase (PON1). 
 
RESULTS: Median age was 39 (30-48) and most had 9 years of education or less (65.5%). 54% of the 
participants were OP pesticide applicators. There was a low prevalence of the GST null genotype 
(GSTT-1% and GSTM-16%) and the GA and GG genotype for NAT (10%). Modulation of OP exposure 
and neurotoxic outcome relationships by NAT, PON1 at position 192 and GST was indicated in 
multivariate analysis. The strongest evidence of modification was by NAT on the relationship between 
pesticide poisoning and impaired vibration sense. Poisoned individuals with the GG genotype were 
more likely to suffer from impaired vibration sense compared to GA and AA genotypes.  
 
CONCLUSION: Genetic polymorphisms of NAT, PON1 (at position 192) and GSTM may modify the 
relationship between OP exposure and neurotoxicity. This however requires further exploration in 
larger longitudinal studies and preventive strategiesto reduce pesticide exposure amongst vulnerable 
groups should be implemented.  
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1. Introduction 
 
Worldwide, organophosphates (OPs) are the most widely used class of pesticide (Costa et al. 2003; 
Mackness et al. 1997; Singh et al. 2011a). Exposure to OP pesticides have been associated with a wide 
range of neurotoxic outcomes such as neurodegenerative diseases (Parkinson's disease and 
Alzheimer's disease) (Baldi et al. 2003; Freire and Koifman 2012; Le Couteur et al. 1999), impairment 
in memory and concentration (Abdel Rasoul et al. 2008; Bouchard et al. 2011), depression and anxiety 
(Mackenzie Ross et al. 2010) and negative effects on the peripheral somatosensory function (Stephens 
et al. 1995; Stokes et al. 1995). Results of studies investigating long-term OP neurotoxicity have 
however been inconsistent, with some studies showing no association between outcomes and 
exposure and others showing an association (Godoy et al. 2014; Holtman 2013). 
 
Evidence from animal studies suggest that susceptibility to the toxicity of OPs may be influenced by 
xenobiotic metabolising enzymes (XMEs) (Costa et al. 1990; Gan et al. 1991; Wei et al. 2001). XMEs 
are enzymes capable of detoxifying metabolites of several OPs. These XMEs include glutathione S-
transferases (GST), N-acetyltransferases (NAT2) and Paraoxonase (PON1) (Costa et al. 2003; Singh et 
al. 2011a; Singh et al. 2011b; Singh et al. 2012). Furthermore, the catalytic efficiency of these enzymes 
have been shown to be determined by their genetic polymorphisms or variations in human 
populations (Abdel Rasoul et al. 2008; Humbert et al. 1993).  
 
Two polymorphisms affect the activity of PON1, the glutamine (GLU)/Arginine (ARG) substitution at 
position 192 (PON1-192Q/R) and the leucine (LEU)/methionine (MET) substitution at position 55 
(PON1-55L/M) (Costa et al. 2005). The LEU/MET polymorphism is responsible for PON1 levels in 
plasma and the GLU/ARG polymorphism determines catalytic efficiency. Leucine has been associated 
with higher PON1 plasma levels when compared to methionine, but the efficiency of the GLU/ARG 
polymorphism is substrate specific. Arginine has been shown to hydrolyse the organophosphate 
paraoxon more rapidly, while glutamine metabolises diazinon, sarin and soman at a more rapid rate 
(Costa et al.1999; Costa et al. 2003). 
 
Although very few epidemiological studies have been conducted to determine the effects of the 
polymorphism on OP toxicity, all the studies reported the importance of PON1 and its polymorphism 
on OP susceptibility (Lee et al. 2003; Leng and Lewalter 1999; Mackness et al. 2003; Singh et al. 2011b; 
Sozmen et al. 2002).  
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Furthermore, these studies were conducted in different settings, used different study designs and 
investigated different health outcomes. The studies were done on individuals exposed to OPs through 
sheep dipping in UK (Mackness et al. 2003), poisoning through suicide attempts (either orally or 
through an injection) in Turkey (Sozmen et al. 2002), OP sprayers for public health programmes in 
India (Singh et al. 2011b) and South African farm workers (Lee et al. 2003). However, none of these 
studies investigated neurobehavioural performance as an outcome of interest. 
 
 In addition to PON1, GST and NAT2 are XMEs capable of detoxifying OPs (Abel et al. 2004; Abhishek 
et al. 2010; Singh et al. 2012). In humans, there are four distinct classes of GST: alpha (A), mu (M), pi 
(P) and theta (T). Genetic polymorphisms of the mu (GSTM1) and theta (GSTT1) group exist and are 
well documented in literature (Abhishek et al. 2010). The variation in these enzymes are due to gene 
deletions resulting in null genotypes. Individuals with the null genotypes are suspected to be more 
susceptible to effects of OPs due to its reduced metabolising properties (Abel et al. 2004; Singh et al. 
2011a).   
 
 
Four epidemiological studies were conducted to determine whether GST (GSTM1 and GSTT1) and 
NAT2 modifies OP neurotoxicity and the results differ between these studies. In India, Abhishek et al. 
(2014) found that GSTT1 played an important role in OP susceptibility but GSTM1 had no effect on 
DNA damage. The OP exposed individuals, with the GSTT1 null genotype showed higher DNA damage 
compared to those with the GSTT1 positive genotype (% DNA in tail 14.43 vs 9.82, p-value<0.05). In 
contrast, Godoy et al. (2014) found no association between the GST (GSTT1 and GSTM1) 
polymorphisms and pesticide intoxication among individuals occupationally exposed to OPs in Brazil.  
 
 
The remaining two studies investigated DNA damage among OP pesticide applicators (Singh et al. 
2011a; Singh et al. 2012) and found that GSTM1 played a significant role in OP susceptibility, as DNA 
damage was higher among individuals with the GSTM1 null genotype. GSTT1 and NAT2 had no effect 
on DNA damage caused by OP exposure. However, OP exposed individuals with the concomitant 
GSTM1 and GSTT1 null genotypes experienced higher levels of DNA damage than those with the 
positive genotypes. Similarly, DNA damage was higher among those with the GSTM1 null genotype 
and the NAT2 slow acetylators (Singh et al. 2011a; Singh et al. 2012). 
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Even though South Africa is the largest consumer of pesticides in sub-Saharan Africa, only one study 
has investigated the effect of xenobiotic enzymes, PON1, on OP neurotoxicity in the country (Lee et 
al. 2003; Naidoo and Buckley 2003). Furthermore, no previous epidemiological studies have 
investigated the effect of XMEs genetic polymorphisms on performance on neurobehavioural tests 
and vibration sensitivity.  The aim of the present study was to determine whether the genetic 
variations of the xenobiotic enzymes (GST: GSTM1 and GSTT1, NAT2 and PON1: PON1-55 and PON1-
192), modulate the relationship between long-term OP exposure and neurobehavioural outcomes and 
vibration sensitivity, amongst emerging farmers in the rural Western Cape of South Africa. 
 
2. Materials and methods 
 
2.1. Study design, population and sampling 
 
This cross-sectional study formed part of a larger cohort study investigating the neurobehavioural 
effects of occupational OP pesticide exposure on emerging farmers in the Western Cape, South Africa 
(Holtman 2013). This sub-study used data collected at baseline in the cohort study to investigate the 
effect of genetic polymorphisms of XMEs on neurotoxicity resulting from long-term exposure to OPs.  
This study received ethical approval by the Research Ethics Committee, Health Sciences Faculty of the 
University of Cape Town (HREC REF 386/2015).  
 
 
In 2009, we recruited participants from three (Overberg, Cape Winelands and the West Coast) of the 
six districts in the Western Cape. This was done by contacting farmer projects registered with the Land 
Reform Office in South Africa. The crops produced on the farms were representative of that produced 
in the Western Cape (Holtman 2013). Furthermore, the farmer projects in these districts had not 
switched to organic methods of crop production. Lastly, the three selected districts were located close 
to Cape Town which facilitated data collection. 
 
 
Of the 34 eligible registered farmer projects in the selected districts, 21 agreed to participate in the 
study. The 21 farmer projects housed 326 farmers and farm workers, all of whom agreed to 
participate. Written informed consent was obtained in English or Afrikaans from each individual 
before the study commenced. 
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2.2.  Demographic and confounder information 
 
All participants were asked to complete a questionnaire in their preferred language, administered by 
a trained interviewer. The questionnaire (Appendix A) consisted of standard demographic information 
(gender, age, language and education level), illnesses (any previous head injuries and psychiatric 
illnesses), lifestyle factors (alcohol consumption, smoking and other drugs) and socioeconomic 
information (possession of the following household appliances: television, electricity, computer and a 
telephone landline).  
 
2.3. Exposure information  
 
The work history section of the questionnaire comprised of questions on the current and four previous 
occupations (occupation type and number of years worked). If the work was performed on a farm, 
there were further questions on: type of crop produced on the farms, job title, tasks or activities 
performed, the number of days doing general farm work or applying specific pesticides (mixing, 
spraying) and the use of personal protective equipment (PPE). The cumulative number of days worked 
was determined retrospectively. The participants were questioned on how many days per week, 
weeks per month and months per year worked. Furthermore, the number of years worked were also 
recorded and the numbers of days worked (8 hour days), and therefore days exposed to pesticides, 
calculated. The exposure days were then weighted using a Job-exposure-matrix (JEM), which was 
adapted from the matrix previously developed for a study conducted on farm workers in the rural 
Western Cape. The JEM measurement has been shown to be repeatable in settings like the rural 
Western Cape (London and Myers 1998).  
 
The exposure indices generated using the JEM included: the accumulated number of working days 
weighted by job activity (JEM days), JEM days weighted by crop usage in 2009 (JEM crop days) and 
JEM and crop days per annum of work life. The exposure measurement per annum was used as an 
index of the intensity of occupational exposure to OP pesticides. The pesticide exposure 
measurements were weighted for the following tasks: mixing pesticides indoors or outside, applying 
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pesticides with a backpack, spraying pesticides with a tractor using hand-directed or a quad bike 
(Mixing indoors = 1.00, Mixing outdoors = 0.80, Tractor spraying with mist blower or boom sprayer = 
0.70, Backpack spraying = 0.70 and Quadbike spraying = 0.70). All other tasks were given a weighting 
of zero. 
2.4. Neurobehavioural assessment 
 
Previous studies have shown that cumulative exposure to OPs can cause neurobehavioural deficits 
such as impairment of one’s attention, memory and concentration (Bouchard et al. 2011; Abdel Rasoul 
et al. 2008). Therefore, neurobehavioural performance was assessed using two tests drawn from the 
World Health Organisation Neurobehavioral Core Test Battery (WHO NCTB), digit span forward and 
digit span backward. The two-digit span tests assess both attention and memory; and are pen and 
paper-based tests that are conducted orally. They are therefore easily used in developing countries 
and have been shown to consistently identify neurotoxicity among exposed individuals (London et al. 
1997). Furthermore, the totals of the two tests were combined and standardised (for the participants’ 
age and gender) to form the digit span Wechsler Ault Intelligence Scale (WAIS) score. From Holtman 
(2013), 43% of the studies that used the digit span forward test found a positive association between 
the test and OP exposure. In addition, digit span WAIS was also positively associated with exposure 
measurements. These two tests, digit span forward and digit span WAIS, were therefore used to assess 
neurotoxicity in this study. 
 
OP exposure can also lead to decreased peripheral somatosensory function. Previous studies have 
confirmed this and shown an association between OP exposure and reduced vibration sense 
(Steenland et al. 1994; Stokes et al. 1995). We therefore conducted vibration sense testing in addition 
to the neurobehavioural tests, in this study. We used a 256-Hz frequency tuning fork to measure 
vibration sensitivity; by applying it to the participant’s non-dominant lower limb. 
 
2.5. Polymorphisms in XME genes  
 
DNA was isolated from peripheral blood lymphocytes of individuals with the Puregene® DNA 
Purification Kit (Gentra Systems, Minneapolis, USA) according to the manufacturer’s specifications.  
Standard DNA quality control measures included spectrophotometry for quantification and agarose 
gel electrophoresis for integrity determination.  DNA stock samples were stored at -80°C for the long-
54 
 
term and retrieved from storage for genotyping assays. For the amplification of the PON1rs854560 
(p.Leu55Met) and PON1rs662 (p.Gln192Arg), 100ng of template DNA was included in a final 
polymerase chain reaction (PCR) volume of 25µl containing; 1x GoTaq buffer (Promega®), 200µM of 
each deoxynucleotide triphosphate (dNTPs), 0.5 units of GoTaq DNA polymerase and 0.4µM of each 
oligonucleotide.  The DNA template was denatured at 95°C for 5 min and amplified for 30 cycles 
consisting of 94°C for 30sec, Ta for 30sec and 72°C for 40sec.   
 
A final step at 72°C for 7min was included to complete the extension of all DNA fragments.  The PCR 
for all polymorphisms were completed on the GeneAmp® PCR System 9700 thermal cycler (Applied 
Biosystems, Foster City, CA, USA).  The PCR fragment containing the PON1 polymorphism rs854560 
(p.Leu55Met) was digested with NlaIII (New England Bio Labs, Cambridge, UK).  Similarly, PON1 
polymorphism rs662 (p.Gln192Arg) were genotyped by the digestion of PCR fragments with AlwI (New 
England Bio Labs).  All the resulting products were separated on an 3% (w/v) SeaKem® LE Agarose 
(Lonza, Basel, Switzerland) gel and visualized with the nucleic acid stain, ethidium bromide (0.5µg/ml; 
Sigma-Aldridge, St. Louis, MO, USA). 
 
The null alleles for GSTT1 and GSTM1 were assayed by co-amplification of the β-Globin gene [3].  In 
this assay 100ng of template DNA is amplified in a final reaction volume of 25µl containing 0.4µM of 
each primer for β-Globin and GSTT1/ GSTM1. The amplified products for the GSTT1 assay were 
separated on a 1% (w/v) SeaKem® LE Agarose (Lonza) gel, whilst GSTM1 was assayed on a 2% agarose 
(Lonza) gel and visualized with the nucleic acid stain, ethidium bromide (0.5µg/ml; Sigma-Aldridge). 
 
The NAT2 polymorphism, rs1799931 p. Gly286Glu, was genotyped by digestion of the PCR fragment 
with BamHI (New England Bio Labs) and subsequent visualization of the products on a 2% (w/v) 
agarose (Lonza) gel.  PCR fragments containing rs1799931 were amplified from 100ng template DNA 
in a final reaction volume of 25µl containing 0.4µM of each primer. 
 
3. Statistical Analysis Section 
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Univariate (histograms and contingency tables) and bivariate (box plots, scatter plots and two tailed 
t-test) exploratory analysis was performed. All outcome variables (vibration sensitivity, digit span 
forward and WAIS) were continuous and transformed to binary variables using the median value as 
the cut-off value (≤ median). Therefore, both linear and logistic regression was used to determine the 
effect of genetic polymorphisms on OP neurotoxicity. Exposure variables included pesticide and OP 
pesticide applicator status; and continuous pesticide and OP exposure variables (JEM days, JEM crop 
days and JEM crop days per annum). The continuous OP exposure variables were transformed to a 
five level categorical variable consisting of a non OPapplicator category and four categories based on 
the quartiles of the OP JEM days of the applicators.  
 
 
Due to the small number of participants with the AA genotype for both NAT and PON1-192, the 
participants with the AA and GA genotypes were grouped together and compared to those with the 
GG genotype. Similarly, MM and LM genotypes for the PON1-55 were grouped together. These 
groupings may differ to that in previous studies. This is largely due to the different study settings, 
which results in different dominant and non-dominant alleles. If too few participants have a particular 
allele, the two non-dominant groups are then grouped and compared to the dominant allele.  
All analyses were conducted using the statistical software package, STATA 13 (StataCorp. 2013. Stata 
Statistical Software: Release 13. College Station, TX: StataCorp LP). The confounders were identified 
in two ways; based on a priori and variables with a significant (p  0.05) association with the outcome 
and exposure variables. The confounders identified from the literature were: gender, age, education, 
language, smoking, psychiatric illness, current alcohol consumption, the CAGE score, previous head 
injury and low socioeconomic status (London et al. 1998; Steinweg and Worth 1993). 
 
 
To test for XMEs effect modification, exposure-gene interaction terms were created by multiplying 
the genetic variables with the exposure variables; OP applicator and the five level categorical OP JEM 
day variables. These interaction variables along with the genetic variables, were included in the model. 
Furthermore, the models were stratified by the different categories of the five XMEs (GSTM1, GSTT1, 
NAT2, PON1-55 and PON1-192) to identify any vulnerable genetic groups.  
 
Diagnostics tests were used to assess model fit and sensitivity analysis. The tests showed that the 
results do not change when classifying the participants who could not identify the pesticides they were 
exposed to, as either exposed, non-exposed or missing. 
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4. Results 
 
4.1. Participation 
 
Most of the participants were from the Cape Winelands district (n=148, 49.2%) followed by the West 
Coast district (n=84, 27.9%) (Table 1).   Of the 326 participants that agreed to participate, 7 did not 
complete the questionnaire and outcome assessment at study commencement. Furthermore, 11 
participants did not provide blood samples and an additional 7 participants were excluded from the 
analysis due to poor DNA amplification or because the DNA could not be located. Therefore, 301 
(92.3%) of the participants eligible to participate in the study was retained.   
 
4.2. Demographic and socioeconomic characteristics 
 
Most of the participants were males (n=204, 67.8%), Afrikaans speaking (n=262, 87.0%) and the 
median age was 39 (30-48) years (table 1). Approximately two thirds of the participants smoked 
and/or consumed alcohol. Less than 12.0% of the participants reported previous head injuries and 
1.7% reported having a psychiatric illness. About 13.0% owned 3 or less items (television, landline 
telephone, cellphone, fridge or electricity) and were classified as having the lowest socioeconomic 
status of the participants. 
 
4.3. Neurobehavioural outcomes and Genetic polymorphisms 
 
The distribution of neurobehavioural performance scores and XMEs genetic polymorphisms are 
shown in Table 2. The scores for digit span forward and digit span WAIS varied over a narrow range 
(5-7 and 6-8, respectively) while vibration sensitivity was more variable (9.5-16.5).  
Less than 20.0% of the participants had the GST null genotypes; GSTT1 (1.3%) and GSTM1 (16.0%). 
Few participants had the MM genotype for PON1-55 (<3.0%) and AA genotype for NAT2 (<1.0%) and 
PON1-192 (11.0%). The GG genotype was predominant for both NAT2 (90.4%) and the PON1-192 
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polymorphism (45.9%). About 70.0% of the participants had the LL genotype for PON1 polymorphism 
at position 55. 
 
 
Table 4: Demographic, Lifestyle and Socioeconomic factors 
Variable N  % 
Demographic Variables 
Gender 
Male 204 67.8 
Female 97 32.2 
Age (years) 39 * 30.0-48.0 ** 
Language 
English 0 0 
Afrikaans 262 87.0 
Xhosa 31 10.3 
Zulu 0 0 
Sotho 8 2.7 
Education 
≤9 years education 197 65.5 
>9 years education 104 34.6 
District 
Overberg 69 22.9 
Cape Winelands 148 49.2 
West Coast 84 27.9 
Lifestyle Factors 
Alcohol Consumption 
Current Alcohol 
consumption 
188 62.5 
Smoking Habits Current Smoker 201 66.8 
Injuries and Illnesses 
Previous Head Injuries Reported Head Injury 35 11.6 
Psychiatric Illness Reported Illness 5 1.7 
Socioeconomic Status Owns ≤3 items  37 12.3 
Items for the socioeconomic performance: television, landline telephone, cell phone, fridge or electricity 
* median in years 
** Interquartile range in years 
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Table 5: Descriptive information of neurobehavioural outcomes and genetic polymorphisms 
Neurobehavioural Outcomes Median (IQR) 
Digit Span Forward score 6.0 (5.0-7.0) 
WAIS Digit Span score 6.0 (6.0-8.0) 
Vibration Sensitivity score 13.0 (9.5-16.5) 
Gene variables Polymorphism  N (%) 
GSTT1 
NULL 4 (1.3) 
YES  297 (98.7) 
GSTM1 
NULL 48 (16.0) 
YES  253 (84.1) 
NAT2 
GG 272 (90.4) 
GA 27 (9.0) 
AA 2 (0.7) 
PON1-55 
LL 209 (69.4) 
ML 84 (27.9) 
MM 8 (2.7) 
PON1-192 
GG 138 (45.9) 
GA/AG 130 (43.2) 
AA 33 (11.0) 
 
4.4. Occupational and pesticide exposure information 
 
Of the 301 participants, approximately 54.0% of the participants were pesticide applicators in their 
previous or current employment and 22.3% were current OP applicators. About 94.0% (n=283) of the 
participants worked on a farm and of these workers, almost half were pesticides applicators (53.2%). 
The rest were farm workers who worked in the field as non-applicators (38.9%) or as general workers 
(2.0%). Of the participants that did not work on a farm (n=18), less than 1.0% worked in the industry, 
3.0% had other forms of employment, 2.0% were pensioners and less than 1.0% were unemployed.  
 
Almost 12.0% reported having been diagnosed with pesticide poisoning in the past and more than 
50% of the pesticide applicators worked 543 days, while the OP applicators worked a total of 308 days.  
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Furthermore, of the past and current pesticide applicators (n=141), less than 1.0% had the GSTT1 null 
genotype and 14.0% had the GSTM1 null genotype. Among the current OP applicators (n=67), 1.5% 
had the GSTT1 null genotype and 16.4% had the GSTM1 null genotype.  All the participants that were 
diagnosed with previous pesticide poisoning (n=22) did not have the GSTT1 null genotype, but 9.1% 
had the GSTM1 genotype.  
 
4.5. Multivariate relationship between OP pesticides exposure and 
performance on neurobehavioural tests  
 
The multivariate results for the association between pesticide exposure and neurotoxic outcomes, 
adjusted for confounders and effect modification by polymorphisms in XME genes, using continuous 
and categorical outcomes and exposure variables, were essentially the same.  Therefore, the results 
of the logistic regression analysis are presented in the paper, as these associations were the strongest. 
 
The logistic regression analysis results for the association between neurotoxic outcomes and OP 
pesticide exposure are presented in Table 3. Table 3 shows that the only significant association 
between OP pesticide exposure and neurotoxic outcome were: a) between vibration sense testing and 
past pesticide poisoning and b) between vibration sense and OP applicators with JEM exposure days 
between the 50th-75th percentile. The individuals previously poisoned were 3.2 fold more likely to have 
a low score for vibration sense testing compared to those not poisoned. Furthermore, the 
performance on the vibration sense test worsens with increased exposure to OPs in a dose dependent 
manner (OP JEM days percentiles: <25th: OR=1.1; CI=0.4-3.2, 25th-50th: OR=2.3; CI=0.7-7.1, 50th-75th: 
OR=2.8; CI=0.9-8.2), except for those with OP JEM days greater than the 75th percentile (OR=0.6; 
CI=0.2-1.8). The association between vibration sensitivity and OP JEM days between the 50th and 75th 
percentile was near significance.  
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4.6. Multivariate relationship between OP pesticides exposure and 
performance on neurobehavioural tests modified by XMEs 
 
A summary of the logistic regression analysis results for the association between neurotoxic outcomes 
and OP pesticide exposure, adjusted for confounders, modified by XMEs polymorphisms is presented 
in Table 4. The models were selected based on the following criteria: a) a change in the odds ratio for 
the exposure variable  in the model containing XME interaction terms compared to the model  that 
does not include the XME interaction terms and b) significant interaction terms. 
 
Table 4 shows that the PON1 polymorphism at position 192 may modify the relationship between OP 
applicator and performance on digit span forward. The odds ratio changed from a negative 
association, 0.7 (95% CI: 0.4 - 1.2) to 1.3 (95% CI: 0.6 – 3.0) after including the interaction term for 
PON1-192. Similarly, NAT2 may modify the relationship between past pesticide poisoning and 
vibration sensitivity as the odds ratio changed from 3.2 (95% CI: 1.1 - 9.1) to a statistically significant 
4.7 (95% CI: 1.3 – 16.9), after adjusting for the genetic polymorphism. However, none of the XMEs 
modified the relationship between the exposure variables and the outcome digit span WAIS. Table 4 
also shows that GSTM1 may modify the relationship between OP JEM days and vibration sensitivity 
testing. The odds ratio for the participants between the 50th and 75th percentile was 2.8 (95% CI: 0.9 - 
8.2) but changed to a statistically significant 3.1 (95% CI: 1.0 – 9.6), when including the GTSM1 genetic 
polymorphism.  
 
Table 5 shows the relationship between OP pesticide exposure and neurotoxicity stratified by XME 
genetic polymorphisms, for the models in Table 4. The stratified results show that OP applicators with 
the GG genotype for the PON1-192 polymorphism performed   worse on the digit span forward than 
the non OPapplicators with the same genotype (OR=1.1, 95% CI: 0.4-2.8). Although the associations 
were not significant, the OP applicators with the GA or AA genotype performed better on the digit 
span forward test compared to the nonOP applicators (OR=0.4, 95% CI:0.2-0.8). Furthermore, 
previously poisoned participants with the GG NAT2 genotype were 5.7 (95% CI: 1.4 – 22.7) times more 
likely to have impaired vibration sense compared those not poisoned, whereas previously poisoned 
participants with the GA or the AA NAT2 genotype were less likely to have impaired vibration sense 
compared to those not previously poisoned (OR=1.5, 95% CI: 0.1 – 43.2). 
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There were too few participants that had the null GSTM1 genotype, but for those that did not have 
the null genotype there were negative associations between vibration sense and OP JEM days quartile 
exposure groups compared to the base group. For the latter, the exposure response relationship 
increased in a dose dependent manner until the 75th quartile. 
 
Table 6: Multiple Logistic Regression Analysis for the association between neurobehavioural 
outcomes and OP JEM days adjusted for confounders (n =301) 
    Adjusted associations Significant covariates in the model 
Dichotomised  
outcomes: 
Exposure variable: Odds ratio 95% CI   p-value Covariate OR (95% CI) 
Digit Span 
Forward 
OP applicator 0.7 0.37 - 1.21 0.18 None 
  
Digit Span WAIS   OP applicator 0.5 0.23 - 1.08 0.08 Education 2.42 (1.20 - 4.89) 
Vibration Sense 
Test  
OP applicator 1.4 0.78 - 2.51 0.26 Head Injury  0.36 (0.16 - 0.82) 
Digit Span 
Forward 
Past pesticide 
poisoning 
2.1 0.83 - 5.22 0.12 None   
Digit Span WAIS   
Past pesticide 
poisoning 
1.5 0.53 - 4.26 0.44 None   
Vibration Sense 
Test  
Past pesticide 
poisoning 
3.2 1.10 - 9.07 0.03 Head Injury  0.08 (0.02 - 0.41) 
Digit Span 
Forward 
< 25thpercentile 0.8 0.29 - 2.32 0.70 None   
Between 25th-50th 
percentile 
0.9 0.30 - 2.61 0.82     
Between 50th-75th 
percentile 
0.2 0.07 - 0.84 0.03     
> 75th percentile 1.0 0.36 - 2.93 0.95     
Digit Span WAIS 
< 25thpercentile 0.5 0.11 - 1.98 0.30 None   
Between 25th-50th 
percentile 
0.8 0.19 - 2.93 0.68     
Between 50th-75th 
percentile 
1.0 
Omitted, predicts 
failure perfectly 
      
> 75th percentile 1.3 0.41 - 4.05 0.67     
Vibration Sense 
Test 
< 25thpercentile 1.1 0.40 - 3.15 0.83 Head Injury  0.41 (0.18 - 0.94) 
Between 25th-50th 
percentile 
2.3 0.71 - 7.13 0.17     
Between 50th-75th 
percentile 
2.8 0.94 - 8.23 0.06     
> 75th percentile 0.6 0.18 - 1.75 0.32     
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    Adjusted associations Significant covariates in the model 
Dichotomised  
outcomes: 
Exposure variable: Odds ratio 95% CI   p-value Covariate OR (95% CI) 
Base exposure group for OP JEM days: 0 days (non-applicators), OP applicator: 1 = applicator, 0 = non applicator; past pesticide 
poisoning: yes = 1, no =0. 
 
 
Table 7: Summary of Multiple Logistic Regression Analysis models for the association between 
neurobehavioural outcomes and OP JEM days adjusted for confounders, XME polymorphism and 
XME effect modification with the strongest associations (n =301) 
  Adjusted associations 
Significant covariates in the 
model 
Gene 
Dichotomised  
outcomes: 
Exposure variable: 
Odds 
ratio 
95% CI   p-value Covariate OR (95% CI) 
PON1_192 Digit Span Forward 
OP applicator 1.3 0.56 - 2.98 0.55 None   
GA/AA 1.6 0.96 - 2.82 0.07     
Exposure-gene 
interaction 
0.3 0.09 - 0.92 0.04     
NAT Vibration sense 
Past pesticide 
poisoning 
4.7 1.28 - 16.94 0.02 Head Injury  
0.1  
(0.015 - 0.38) 
GA/AA 0.6 0.19 - 1.83 0.36     
Exposure-gene 
interaction 
0.5 0.07 - 2.95 0.41     
GSTM 
Vibration Sense 
Test 
< 25thpercentile 1.2 0.42 - 3.34 0.75 Head Injury  
0.4  
(0.18 - 0.94) 
Between 25th-50th 
percentile 
2.5 0.77 - 7.92 0.13     
Between 50th-75th 
percentile 
3.1 1.02 - 9.60 0.05     
> 75th percentile 0.7 0.21 - 2.27 0.54     
Null 2.5 0.82 - 7.70 0.11     
Exposure-gene 
Interaction 
0.7 0.41 - 1.33 0.31     
Base exposure group for OP JEM days: 0 days (non-exposed participants); for OP applicator: non applicator = 0, applicator = 1 
Base XME genetic groups: GSTM: Yes, NAT and PON1_192: GG and PON1 at position 55: LL 
63 
 
 
Table 8: Summary the relationship between OP pesticide exposure and neurotoxic outcomes 
stratified for XME polymorphism for the models listed in Table 4 (n =301) 
  Adjusted associations 
Gene Neurotoxic Outcomes: Exposure variable: 
Odds 
ratio 
95% CI   p-value 
PON1_192 = GG Digit Span Forward OP applicator 1.3 0.55 – 3.08 0.55 
PON1_192 = GA/ AA Digit Span Forward OP applicator 0.4 0.15 – 0.82 0.02 
NAT = GG Vibration Sense Test Past pesticide poisoning 5.7 1.41 – 22.70 0.02 
NAT = GA/AA Vibration Sense Test Past pesticide poisoning 1.5 0.05 – 43.18 0.83 
GSTM = Yes Vibration Sense Test 
< 25thpercentile 1 0.32 - 3.13 0.99 
Between 25th-50th percentile 1.8 0.54 - 6.09 0.34 
Between 50th-75th percentile 3.3 0.95 - 11.44 0.06 
> 75th percentile 0.8 0.23 - 2.59 0.68 
GSTM = Null Vibration Sense Test 
< 25thpercentile 0.9 0.03 - 27.56 0.98 
Between 25th-50th percentile 1 Omitted  
Between 50th-75th percentile 2.7 0.15 - 49.74 0.5 
> 75th percentile 1 Omitted 
Base exposure group for OP JEM days: 0 days (non-exposed participants); for OP applicator: non applicator = 0, applicator = 1 
 
 
5. Discussion 
The results of the study indicate effect modification by PON1-192, NAT2 and GSTM1. There was a 
strengthened association between OP pesticide exposure and the neurotoxic outcomes, digit span 
forward and vibration testing (Table 5), after accounting for the genetic polymorphisms of these 
enzymes.  
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Firstly, low digit span forward scores were more prevalent among applicators compared to non-
applicators among individuals with the GG genotype for the PON1 polymorphism at positon 192. This 
indicates that neurotoxicity increases with OP exposure for this group of workers. This relationship 
was not seen among the individuals with the AA and GA genotypes. Therefore, the individuals with 
the GG genotype at position 192 on the PON1 gene, may be more sensitive to OP toxicity. This result 
is consistent with the laboratory studies that have shown that the AA genotype hydrolyses paraoxon 
more rapidly than the GG genotype (Costa et al. 2003; Costa et al. 2005).   
 
The finding is also consistent with three of the previous observational studies conducted, one of them 
conducted in the Western Cape, of South Africa (Lee et al. 2003; Mackness et al. 2003). The cross-
sectional study done in South Africa showed that the participants with the homozygous PON1-192 GG 
or heterozygous PON1-192 GA genotypes were almost three times more likely to report symptoms 
that were associated with chronic OP poisoning compared to those with the homozygous PON1-192 
AA genotype (CI: 1.7 – 6.9). The case-control study by Mackness et al. (2003) found that individuals 
with the PON1-192 GG and PON1-192 GA amino acid combination were 2.39 (95% CI = 1.46 – 3.98) 
times more likely to reporting chronic ill health than those with the PON1-192 AA combination among 
sheep dipping farmers in the United Kingdom occupationally exposed to OPs. Furthermore, a cross 
sectional study conducted in New Delhi, India by Singh et al. (2011b) among OP sprayers for public 
health programmes and controls found participants with the 192GG genotype had a higher prevalence 
of DNA damage (Singh et al. 2011b). 
 
The second set of evidence for XMEs effect modification is the strengthened relationship between 
pesticide poisoning and impaired vibration sensitivity when adjusting for NAT2 polymorphism. 
Furthermore, stratifying by the genetic polymorphism of NAT2 showed a stronger positive relationship 
between OP poisoning and impaired vibration sensitivity for those with the GG genotype compared 
to those with the GA and AA genotype. This finding is consistent with that of Singh et al. (2012) who 
investigated DNA damage among OP pesticide and found that DNA damage was higher among those 
with the NAT GG genotype. However, it should be noted that few farmers had the AA and the GA 
genotype in our study (less than 10%).  
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The third finding in our study indicating effect modification by XMEs, was the reduced vibration 
sensitivity, due to increased OP exposure (as measured by JEM days), among those with the GSTM1 
positive genotype compared to those with the null genotype.  This is in contrast to the finding from 
three of the four studies that investigated the effect of GST on OP neurotoxicity. The studies found 
that the GSTM1 null genotype was associated with increased DNA damage (Abhishek et al. 2014; 
Godoy et al. 2014; Singh et al. 2011b; Singh et al. 2012). The low prevalence of the GTSM1 (16%) null 
genotype found in our study could have produced spurious findings. 
 
 
This study did not find any evidence of effect modification by the genetic polymorphisms of GSTT1 
and PON1-55.  Previous studies investigating the role of the GST enzymes have produced inconsistent 
results.  Abshishek et al. (2010) found that GSTT1 modified OP exposure and DNA damage and Singh 
et al. (2011a; 2012) found no association with GSTT1.  Again, the prevalence of GSTT1 (<2%) in this 
population was low. Previous epidemiological studies have however found that the PON1 
polymorphism at position 55, played a role in the modification of OP neurotoxicity. In Turkey, 
participants with the PON1-M55 genotype were more likely to suffer from OP intoxication (likelihood 
ratio=4.721, P=0.094) (Sozmen et al. 2002) and in India the OP sprayers with the PON1-L55 genotype 
showed higher PON1 activity and therefore lower prevalence of DNA damaged (Singh et al. 2011a). 
However, OP exposed sheep dippers in the UK with the PON1-L55 genotype were approximately 3 
(95% CI=1.88 – 5.31) times more likely to be a case, of reported chronic ill health, compared to those 
with the PON1-L/M55 and the PON1-M55 genotypes (Mackness et al. 2003). 
 
Also, for most of the neurobehavioural outcomes, this study did not find evidence of effect 
modification by PON1-192, NAT2 and GSTM1. The low prevalence of some of the OP genotypes in the 
population of emerging farm workers in our study might have affected the findings on effect 
modification. Less than 2% of the participants had the GSTT1 null genotype and there was therefore 
not enough variability in the sample to determine the effects of its genetic polymorphism on OP 
neurotoxicity. Furthermore, with NAT2 and PON1 (at positions 55 and 192), too few participants had 
the AA genotype (<1%, <3% and 11% respectively). We were therefore unable to compare the 
performance of these participants to the other genetic groups. In the analysis, individuals with the AA 
genotype for NAT2 and PON1 (192) were grouped together with the GA participants and then 
compared to the participants with the GG polymorphism.  
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Similarly, with the PON1-55 polymorphism, participants with MM and LM genotypes were grouped 
together and their results compared to those with the LL genotype.  Therefore, in this study, it was 
not possible to determine the individual effects of each genotype.  
 
To our knowledge, this is the first study to look at the effects of genetic polymorphisms on the 
relationship between long-term OP pesticide exposure and neurobehavioural performance. Previous 
studies have investigated the effect of XMEs genetic polymorphisms on the relationship between OP 
pesticide poisoning and outcomes such as such as DNA damage (Lee et al. 2003; Singh et al. 2011a). 
 
The only significant association between long-term pesticides exposure and a neurotoxic outcome in 
our study, was an association between past pesticide poisoning and performance on the vibration 
threshold test for those with the GG genotype for NAT. The poisoned individuals showed a significant 
decrease in vibration sensitivity. Previous studies have consistently shown negative neurobehavioural 
effects associated with OP poisoning (Colosio et al. 2009) but not consistently with an OP exposure 
index that does not specifically focus on poisoning. In our study, there was a borderline significant 
negative association (p = 0.06) between vibration sense and OP JEM days in the 3rd quartile and dose 
response relationship below the 4th quartile for those with the positive GSTM genotype. 
 
In addition to the low prevalence of some XMEs genotypes, the most important limitations of the 
study were the OP exposure characterisation, reliance on self-reported information and the study 
design. Long-term pesticide exposure information is particularly difficult to measure as the 
measurement is reliant on participant’s recollection of past pesticide use which may be subject to 
recall bias. Including pesticide bio-monitoring in the study may enhance exposure estimation.  
 
Information on confounders such as alcohol consumption and smoking may be subject to a desirability 
bias, where individuals report to not have smoked or consumed alcohol, when they have. The 
measurement of these confounders are particularly important as alcohol consumption can influence 
performance on the neurobahvioural tests, and smoking may be linked to neuropathy (National 
Institute of Neurological Disorders and Stroke 2016), therefore influencing vibration sensitivity. 
However, the desirability bias is unlikely associated with OP exposure. 
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Lastly, the study design was a cross-sectional one. We could therefore only measure associations at 
one particular point in time. A longitudinal design where the outcomes and exposures are measured 
and monitored repeatedly may produce more accurate results. 
 
6. Conclusion 
 
This study has provided evidence that the XMEs, in particular PON1-192, NAT2 and GSTM1 may modify 
OP neurotoxicity. In order to identify susceptible populations and determine whether preventative 
strategies can be developed for the vulnerable groups, larger longitudinal studies and repeated 
pesticide bio-monitoring are needed for these gene-exposure interaction studies.  
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Neurobehavioural effects of pesticide exposure among emergent 
farmers in the Western Cape 
 
Farmer Questionnaire 
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Questionnaire Number   
 
 
District 
 
 
Date 
 
            
Farm (Trust/project)  
name    
  
Name of Farmer 
 
 
 
 
Cell phone number       
 
Telephone number 
(landline) 
 
Name of Interviewer                   
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GENERAL INSTRUCTIONS 
 
Thank you for agreeing to take part in this study. 
 
We will work through the questionnaire as follows: I will ask the questions and give you the 
answer choices and tick or circle the answers you give me in the questionnaire. Choose the 
answer that is the closest to how you feel. The interview will take between forty five minutes 
and one hour to complete.  
 
Please note that there are no right or wrong answers to the questions asked. Please feel free to 
answer just what you think. You may stop at any time if you do not want to carry on with these 
questions. Your answers are confidential and will not be shared with anyone. Only the research 
staff will have access to the questionnaire once it has been completed.    
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Section 1:  DEMOGRAPHIC CHARACTERISTICS 
 
We would like to ask you a few questions about yourself. 
 
Please circle the correct response. 
1.1    Gender            Male / Female 
 
1.2    How old are you? _________years   
        Date of birth  ____/_____/_____ 
 
1.3   What is the highest level of education you have passed? 
Less than one year completed 1 
Sub A/Class 1/Grade 1 2 
Sub B/Class 2/Grade 2 3 
Standard 1/Grade 3 4 
Standard 2/Grade 4 5 
Standard 3/Grade 5 6 
Standard 4/Grade 6 7 
Standard 5/Grade 7 8 
Standard 6/Grade 8 9 
Standard 7/Grade 9 10 
Standard 8/Grade 10 11 
Standard 9/Grade 11 12 
Standard 10/Grade 12 13 
Further studies – incomplete 14 
Diploma/other post school – complete 15 
Degree 16 
 
 
1.4 Which of the following is the main language spoken at home? (Please circle   
        only one)   
 
            English 1 
Afrikaans 2 
IsiXhosa 3 
IsiZulu 4 
SeSotho 5 
SeTswana 6 
SePedi 7 
SiSwati 8 
TshiVenda 9 
Zitsonga 10 
IsiNdebele 11 
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Other (Please specify) 12 
 
 
 
 
Section 2: HOUSEHOLD FACTORS 
 
2.1       Is the house you live in:  
  
Owned by your family  
 
1 
Rented  
 
2 
Owned by the owner of the farm 3 
Other (please specify) 4 
 
2.2     How many rooms are there in this house? 
 
 Rooms 
 
2.3 How many bedrooms are there in this house?   
 
 Bedrooms 
 
2.4 How many bathrooms are there in this house?  
 
 Bathrooms  
2.5 Does your house have: 
  Yes No 
A Electricity   
B A radio   
C A television   
D A landline telephone   
E A fridge   
F A computer   
G A washing machine   
H A cell phone (anybody) 
 
  
  
 
 
 
2.6  Which of the following live in the same household with you?  
  Yes No 
A Live alone   
B Partner   
C Child or Children under 13 yrs   
D Child or Children over 13 yrs   
E Brother(s) and/or sister(s)   
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F Mother/Female guardian   
G Father/Male guardian   
H Grandparent(s)   
I Other (please specify)   
 
2.7 How many people usually live and sleep in your household? 
 Number of people 
 
 
 
Section 3:  ECONOMIC FACTORS 
 
Now we would like to ask a few questions about you and the work that you do. 
 
3.1 What kind of work do you do? (If working, please tell me your occupation. For          
example, Farmer, Street Trader, Primary School Teacher, Domestic Worker) 
 
Not working 0 
Working (Please specify) 1 
 
 
3.2   Have you done any paid work in the last 12 months? 
 
No 0 
Yes 1 
 
 
3.3    What kind of paid work did you? 
1.  
2.  
3.  
 
 
3.4     Please indicate which of the following are your sources of income. Please    
              answer this question whether or not you are working.  
 
  Yes No 
A Work   
B Spouse/partner   
C Parents   
D Brothers and/or sisters   
E Children   
F Child Support Grant   
G State Old Age Pensions   
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H Disability Grant   
I Care Dependency Grant   
J Foster Care Grant   
K Grants-in-Aid   
L Workman’s Compensation Fund   
M Other (Please specify)   
 
3.5 How often do the people here go hungry or have no food to eat? 
Never 0 
Seldom 1 
Sometimes 2 
Often 3 
 
3.6 How often does your family have enough money for: 
  Never 
Some- 
times  
Always  
Not 
Applica
ble 
A Buying food 0 1 2 3 
B 
Paying for transport (bus, taxi, 
train fare, petrol bills) 
0 1 2 3 
C 
Paying bills (rent, light, water, 
telephone, etc.) 
0 1 2 3 
D Paying doctors and for medicine 0 1 2 3 
E 
Buying school supplies, uniforms, 
books, shoes 
0 1 2 3 
F Buying clothes 0 1 2 3 
G Buying firewood, coal, paraffin 0 1 2 3 
 
 
 
Section 4. LIFE HISTORY 
 
Now I’d like to ask you a few questions about the places where you have lived in your 
lifetime: 
 
 
4.1  Where do you live now ? _______________________________________ 
 
 
4.2  How long have you lived here? ____________________ _(Years/Months) 
 
 
4.3  What kind of farm is this (what is grown here) ? ______________________ 
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4.4   How far from your house is the vineyard/field ? ______________________ 
 
 
4.5  Are pesticides sprayed on the vineyard/field during the year?         (YES, NO) 
 
                      
IF YES, complete the following: 
 
4.5.1    How many times a year are pesticides applied by means of  
                        a tractor with a boom sprayer ______ (number of times a year) 
 
4.5.2 A tractor with persons using hand or backpacks? _____ (number of  
            times a year) 
 
4.5.3    Aerial spraying (with an aeroplane) _____ (number of times a year) 
 
            4.5.4    Quadbike spraying __________________(number of times a year) 
 
4.6  Does the pesticide spraying come into the house?                           (YES, NO) 
  
4.7  Does any member of your family come into contact with pesticides  
        outside the house while spraying occurs (eg. children playing near  
        spraying area) ?                                                                                  (YES, NO) 
 
4.8 Does any member of your family go into in the field/vineyards  
       soon after spraying or come into contact with sprayed surfaces?       (YES, NO) 
 
4.9 What are the sources of drinking water at your house? ____________________     
      (municipal water, storage dam on mountain, borehole/spring, river water, farm  
      dam, rain water tank, etc) 
4.10 What are the sources of water for recreational use (bathing, washing of clothes)  
         at your house? ____________________  (municipal water, storage dam on  
         mountain, borehole/spring, river water, farm dam, rain water tank, etc) 
 
4.11  Does any other member of your family perform work on the farm? (YES, NO) 
 
            If Yes – list the members who are involved in spraying and/or mixing  
            pesticides? (for example – partner/wife – mixes pesticides or adult member of  
            the family sprays pesticides) 
  
             
Member of family e.g. adult son Activity e.g. sprays pesticides 
  
  
  
  
  
 
 
4.12  Do you work in the pesticide store?                                                 (YES, NO) 
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4.13 Does any member of your family come into contact 
        with empty pesticide containers?                                                      (YES, NO) 
 
        If YES, how _________________________ (for example  
        drinking water, burn empty containers) 
 
4.14 Does any member of your family eat from the crops in the  
        vineyard/field soon after spraying?                                                  (YES, NO) 
 
4.15 Do you wash your hands before you eat?                                        (YES, NO) 
          
 
 
 
Section 5. ALCOHOL USE 
 
5.  Do you drink alcohol ?                                                                       (YES, NO) 
 
5.1 Have you ever felt that you should drink less alcohol?                      (YES, NO) 
 
5.2 Have people ever angered you by criticising your drinking habits?   (YES, NO) 
 
5.3 Have you ever felt guilty or bad because you drink alcohol?             (YES, NO) 
 
5.4 Have you ever had a drink early in the morning to make you  
      feel better or to get over a ‘babalaas’?                                                (YES, NO) 
 
 
 
 Section 6.  SMOKING AND OTHER DRUG USE 
 
 
6.1 Do you smoke ?                          (YES, NO) 
 
 
6.1.1 If YES please state what you smoke:  
 
 YES NO 
Cigarettes   
Pipe Tobacco   
Dagga   
Other, please describe   
 
 
 
6.1.2 If NO did you ever smoke and if so what did you smoke? (YES, NO) 
         (IF you did smoke before please state what you smoked) 
 YES NO 
Cigarettes   
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Pipe Tobacco   
Dagga   
Other, please describe   
 
 
6.2 During the past 30 days, on how many days did you use each of the following     
substances if at all? 
 
 
 
 
Section 7. SUICIDALITY 
 
7.1 During the past 12 months have you ever seriously thought 
      about hurting yourself in a manner that may cause you to die?         (YES, NO) 
 
7.2 During the past 12 months, have you ever told someone that  
      you plan to commit suicide?                                                               (YES, NO) 
 
7.3 During the past 12 months, have you ever tried to commit suicide?   (YES, NO) 
 
 
7.4 Have any of your attempts to injure yourself caused you to be           (YES, NO) 
      treated by a doctor or nurse? 
 
 
 
 
Section 8.  WORK HISTORY 
 
Current job 
8.1  Are you currently working on this farm                                               (YES/NO) 
 
8.1.1  If YES - how long have you been working on this farm (or since when) 
  0 days 
1 or 2 
days 
3 to 5 
days 
6 to 9 
days 
10 to 19 
days 
20 to 29 
days 
All 30 
days 
         
A Dagga 0 1 2 3 4 5 6 
B Mandrax 0 1 2 3 4 5 6 
C Heroin 0 1 2 3 4 5 6 
D Crack/cocaine 0 1 2 3 4 5 6 
E Ecstasy 0 1 2 3 4 5 6 
F 
Methamphetamin
e  (tik) 
0 1 2 3 4 5 6 
 
I 
Other  0 1 2 3 4 5 6 
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                     (If NO – Go to question 8.2) 
                      _________________________________________________________ 
 
8.1.2  Which crops do you work with  _______________________________ 
 
8.1.3  Do you apply pesticides                                                          (YES/NO)  
 
8.1.3.1 If YES which pesticides do you use  ____________________ 
 
 _________________________________________________ 
 
 
 
 
Please provide the details about your CURRENT work with pesticides in the following table 
 
 
Current job – Date: ____________________________ 
 
 
 
 
Activity 
 
 
 
Yes/No 
 
 
Hours per day 
And  
Days per week 
 
 
Weeks per 
month 
And 
Months per 
year 
 
 
Number of   
years 
PPE  Use: 
Indicate which: 
A = Apron 
B = Boots 
G = Gloves 
M = Mask 
O = Overalls 
Gls  = Goggles 
Mix pesticides 
inside 
     
Mix pesticides 
outside 
     
Tractor driver with 
boom sprayer 
     
Tractor driver 
without boom 
sprayer 
     
Quadbike spraying      
Back pack or hand 
spraying 
     
 
 
8.2  If NO – please answer the following questions: 
 
8.2.1 Are you currently also doing a non-farming job                    (YES/NO)   
  
            8.2.2 If yes, where are you working ________________________________ 
 
            8.2.3 What is your job title  ______________________________________ 
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8.3 Please list your PREVIOUS jobs for the last 3 years (excluding your current job)  
      where you handled, mixed or in any way came into contact with pesticides. Start  
      with the job before your current job. 
 
 
 
 
JOB 1 -  Date:___________________   
 
 
 
Activity 
 
 
Yes/No 
 
 
Hours per day 
And  
Days per week 
 
 
Weeks per 
month 
And 
Months per year 
 
 
Number of   
years 
PPE  Use: 
Indicate which: 
A = Apron 
B = Boots 
G = Gloves 
M = Mask 
O = Overalls 
Gls  = Goggles 
Mix pesticides 
inside room 
     
Mix pesticides 
outside room 
     
Tractor driver with 
boom sprayer 
     
Tractor driver 
without boom 
sprayer 
     
Quadbike spraying      
Back pack or hand 
spraying 
     
 
 
JOB 2 -  Date:___________________   
 
 
 
Activity 
 
 
Yes/No 
 
 
Number of 
months per year 
 
 
Number of 
days per week 
 
 
Number of   
years 
PPE  Use: 
Indicate which: 
A = Apron 
B = Boots 
G = Gloves 
M = Mask 
O = Overalls 
Gls  = Goggles 
Mix pesticides 
inside room 
     
Mix pesticides 
outside room 
     
Tractor driver with 
boom sprayer 
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Tractor driver 
without boom 
sprayer 
     
Quadbike spraying      
Back pack or hand 
spraying 
     
 
JOB 3 -  Date:___________________   
 
 
 
Activity 
 
 
Yes/No 
 
 
Hours per day 
And  
Days per week 
 
 
Weeks per 
month 
And 
Months per year 
 
 
Number of   
years 
PPE  Use: 
Indicate which: 
A = Apron 
B = Boots 
G = Gloves 
M = Mask 
O = Overalls 
Gls  = Goggles 
Mix pesticides 
inside room 
     
Mix pesticides 
outside room 
     
Tractor driver with 
boom sprayer 
     
Tractor driver 
without boom 
sprayer 
     
Quadbike spraying      
Back pack or hand 
spraying 
     
 
 
 
 
Section 9. ENVIRONMENTAL EXPOSURE 
 
9.1  Do you use any pesticides in your garden or in your home?             (YES / NO) 
       eg. Target or Doom __________________________ 
 
9.2  For how long have you been using pesticides at home __________ (number of  
       years) 
 
9.3  How frequently do you use pesticides at home __________ (every day, 3 times a  
       week, once a week, once a month, less than once a month) 
  
9.4  Have you taken any empty containers home?                                  (YES / NO) 
 
9.5  If yes, what was it used for  ________________________________________ 
 
9.6  Does any other person in the house work with pesticides?                  (YES / NO) 
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9.7  If yes, how many? ________________________________________________ 
         
9.8 For how long has this person in your home worked with pesticides? _________   
 
__________________(Year(s)) 
9.9   Do pesticide contaminated clothes get washed at home                       (YES / NO)          
    
9.10  If yes, does it get washed with the rest of the washing?                      (YES / NO) 
 
9.11  Do you eat fruit or vegetables from your garden                                 (YES / NO) 
 
9.12  Do you use empty pesticide containers at home for domestic  
         purposes                                                                                               (YES / NO) 
      
9.13  If yes, what do you use them for? _____________________________________ 
        
         ________________________________________________________________ 
 
9.14  For how long have you been using empty containers at home _______ (Year(s)) 
 
9.15 What do you do with the pesticide containers you don’t use anymore 
 
_________________________________________________________ 
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Brief Symptom Inventory (BSI) 
 
(Interviewer write the answer of the worker, according to the given ratings, in the 
appropriate block) 
 
 
NOT AT ALL 
A LITTLE  BIT 
MODERATELY 
QUITE A BIT 
EXTREMELY 
0 
1 
2 
3 
4 
 
 
This is a list of problem that people sometimes experience. Please listen to each one 
Carefully and choose the one which best describes THE EXTENT TO WHICH THIS 
PROBLEM HAS UPSET/DISTURBED YOU DURING THE PAST 7 DAYS, 
INCLUDING TODAY. 
 
1.  Nervousness or shakiness inside    
2.  Faintness or dizziness  
3.  The idea that someone else can control your thoughts  
4.  Feeling others are to blame for most of your troubles  
5.  Trouble remembering things  
6.  Feeling easily annoyed or irritated  
7.  Pains in heart or chest  
8.  Feeling afraid in open spaces or on street  
9.  Thoughts of ending your life  
10. Feeling that most people cannot be trusted  
11. Poor appetite  
12. Suddenly scared for no reason  
13. Temper outbursts that you could not control  
14. Feeling lonely even when you are with people  
15. Feeling blocked in getting things done  
16. Feeling lonely  
17. Feeling blue  
18. Feeling no interest in anything  
19. Feeling fearful  
20. Your feelings being easily hurt  
21. Feeling that people are unfriendly or dislike you  
22. Feeling inferior to others  
23. Nausea or upset stomach  
24. Feeling that you are watched or talked about by others  
25. Trouble falling asleep  
26. Having to check and double-check what you do  
27. Difficulty making decisions  
28. Feeling afraid to travel on buses, subways or trains  
29. Trouble getting your breath  
30. Hot or cold spells  
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31. Having to avoid certain things, places or activities because they  
      frighten you 
 
32. Your mind going blank  
33. Numbness or tingling in parts of your body  
34. The idea that you should be punished for your sins  
35. Feeling hopeless about the future  
36 Trouble concentrating  
37. Feeling weak in parts of your body  
38. Feeling tense or keyed up  
39. Thoughts of death or dying  
40. Having urges to beat, injure or harm someone  
41. Having urges to break or smash things  
42. Feeling very self-conscious with others  
43. Feeling uneasy in crowds such as shopping or at a movie  
44. Never feeling close to another person  
45. Spells of terror or panic  
46. Getting into frequent arguments  
47. Feeling nervous when you are left alone  
48. Others not giving you proper credit for your achievements  
49. Feeling so restless you couldn’t sit still  
50. Feelings of worthlessness  
51. Feeling that people will take advantage of you if you let them  
52. Feelings of guilt  
53. The idea that something is wrong with your mind  
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Q16  SYMPTOMS 
 
   Please circle the correct answer 
      
1. Are you abnormally tired ?                 1. YES  2. NO  
   
2. Do you have palpitations of the heart when you do not exert yourself ?  1. YES  2. NO    
  
3. Do you often have painful tingling in some part of your body ?               1. YES  2. NO   
              
4. Do you often feel irritated without any particular reason ?               1. YES  2. NO  
 
5. Do you often feel depressed without any particular reason ?                   1. YES  2. NO  
   
6. Do you often have problems concentrating ?                         1. YES  2. NO  
 
7. Do you have a short memory ?                 1. YES  2. NO  
 
8. Do you often perspire without any particular reason ?              1. YES  2. NO  
 
9. Do you have any problems with buttoning and unbuttoning ?                  1. YES  2. NO     
 
10.Do you generally find it hard to get the meaning from reading  
     newspapers and books ? 0. standard 4 or less = CANNOT READ         1. YES  2. NO   
   
11.Have your relatives told you that you have a short memory ?                 1. YES  2. NO  
 
12. Do you sometimes feel a heavy feeling on your chest ?                          1. YES  2. NO   
 
13. Do you often have to make notes about what you must remember ?      
      0. standard 4 or less = CANNOT READ                                                    1. YES  2. NO                
 
14. Do you often have to go back and check things you have done such as 
      locking the door ?                   1. YES  2. NO  
 
15. Do you have a headache at least once a week ?                1. YES  2. NO   
  
16. How many times do you have sex per week?_________________      
                                        
16a. Do you think that this is less than most persons of your age?              1. YES  2. NO    
 
 
                       
 
 
Thank you for taking part in this study 
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 APPENDIX B: STUDY INFORMATION SHEETS 
(ENGLISH) 
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STUDY INFORMATION SHEET 
Adult Family member 
 
1. Title of research project 
The title of the study is “neurobehavioural effects of organophosphate pesticides among 
emergent farmers and adult members of their families in the Western Cape.” 
 
2. Purpose of research 
The purpose of this research is to find out whether you and adult members of your family 
have been affected negatively because of coming into close contact with, and/or using 
pesticides. In particular the study will look at the effects of pesticides that we call 
organophosphates on your health as well as the health of adult members of your family. 
  
3. Why the research is important? 
South African farmers, farm workers and their families may be affected by pesticides. 
Emerging farmers or small-scale farmers may be encouraged to use more pesticides in order 
to become commercial farmers. Without the necessary information and training about the 
effects and use of pesticides the health of farmers and members of their family may be at risk. 
Because the effects of using low doses of pesticides over a long period of time are not always 
visible and noticeable farmers and their families may not be aware of the dangers that these 
pesticides may cause to their health.  
    
4. Description of the research project 
The study will take place over twelve months starting approximately December 2008 in the 
following manner: 
At the start of the study, we will do the following: a) ask you to answer question from a 
questionnaire; b) perform some tests of your memory, your thinking and your mood, and your 
movements and administer questionnaires. These visits will take place approximately in 
March, June, September with the last testing taking place in December 2009.   
 
If you agree to participate, and if you give permission for adult members of your family to take 
part in the study, I and four research assistants will administer the following tests to each adult: 
 
 A questionnaire that will take between 30 and 45 minutes each to complete. The 
questionnaire that will ask questions about your age, gender, education, health, 
drinking, smoking practices and work activities, your psychological well-being and 
your general health.  
 Tests of your memory, your thinking your mood, and your movements. These are 
like IQ tests and will not cause any harm to you or your family. These are tests that 
will involve you telling me things, pointing out things and moving your hands.   
 An examiner will test how well you can feel vibration in your ankle using a tuning 
fork  
 
    
Whenever possible, you will be interviewed in privacy in order to complete the questionnaire 
and to conduct the tests. Any personal information will be kept confidential. 
 
 
 
5. Risks and discomforts of the research    
91 
 
There are no risks when completing the questionnaires. However testing will be stopped if 
you as the participant request it and can be continued at a later time or not at all.  If you are 
uncomfortable about any aspect of the testing, intervention or treatment will be made 
available from a trained clinical staff member.  
 
6. Expected benefits to you and others 
This study will try to find out whether you have been affected negatively because of using 
and/or coming into close contact with pesticides in your farming activities and if you have 
been affected, you will be provided with information about pesticides and referred to your 
nearest hospital or clinic if necessary.  It is important that you and adult members of your 
family attend all of these testing sessions to determine the effects of pesticide exposure on 
your health.  
 
7. Costs to you resulting from participation in the study 
You will not be paid or have to pay for taking part in the study.  You will be provided with 
lunch or tea if you have to spend a long time with us in the study. 
 
8. Confidentiality of information collected 
You will not be personally identified in any reports on this study.  The records will be kept 
confidential to the extent provided by law.   
 
9. Documentation of the consent 
A copy of this document will be kept together with my research records on this study.   
 
10. Contact person 
You may contact the following persons for answers to further questions about the research, 
your rights, or any injury you may feel relates to the study. 
 
Professor Marc Blochman (Chairperson of the Research Ethics Committee) 
Telephone: 021 406 6492 
 
Name of researcher: Ms. Zelda Holtman (Student and researcher)      
Telephone: 021 406 6842 
Fax: 021 406 6163 
Email: Zelda.Holtman@uct.ac.za 
 
Name of Principal Co-investigator:  Dr Aqiel Dalvie 
Telephone: 021 406 6610 
Fax: 021 406 6163 
Email: Aqiel.Dalvie@uct.ac.za 
 
 
11. Voluntary nature of participation 
Your participation in this project is entirely voluntary. You must decide whether you want to 
participate or not, without feeling obligated to anyone. You will not suffer any discrimination 
from the extension officers or the health services if you decide you do not want to participate. 
Even if you start participating in the study, you can always change your mind later and 
withdraw from the study.  
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 APPENDIX C: CONSENT FORMS 
(ENGLISH) 
 
 
 
 
 
 
 
Consent Form 
 
Head of Household 
 
 
Consent to participate in study on the neurobehavioural effects of Organophosphate 
pesticides among emergent farmers and adult members of their families. 
 
 
I am a PhD student at the University of Cape Town. I would like to ask you to participate in a 
research study. 
 
1. Title of research project 
The title of the study is “The neurobehavioural effects of organophosphate pesticides among 
emergent farmers and adult members of their families in the Western Cape.” 
 
2. Purpose of research 
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The purpose of this research is to find out whether you and adult members of your family 
have been affected negatively because of coming into close contact with, and/or using 
pesticides. In particular the study will look at the effects of pesticides that we call 
organophosphates on your health as well as the health of adult members of your family.  
 
3. Why the research is important? 
South African farmers, farm workers and their families may be affected by pesticides. 
Emerging farmers or small-scale farmers may be encouraged to use more pesticides in order 
to become commercial farmers. Without the necessary information and training about the 
effects and use of pesticides the health of farmers and members of their family may be at risk. 
Because the effects of using low doses of pesticides over a long period of time are not always 
visible and noticeable farmers and their families may not be aware of the dangers that these 
pesticides may cause to their health.  
    
4. Description of the research project 
The study will take place over twelve months starting approximately December 2008 in the 
following manner: 
At the start of the study, we will do the following: a) ask you to answer question from a 
questionnaire; b) perform some tests of your memory, your thinking and your mood. After 
this initial examination, we will visit you and the adult members of your family who have 
consented to participate every third to fourth month to administer questionnaires. These visits 
will take place approximately in March, June, September with the last testing taking place in 
December 2009 
 
If you agree to participate, and if you give permission for adult members of your family to take 
part in the study, I and four research assistants will administer the following tests to each adult: 
 
 A questionnaire that will take between 30 and 45 minutes each to complete. The 
questionnaire that will ask questions about your age, gender, education, health, 
drinking, smoking practices and work activities, your psychological well-being and 
your general health.  
 Tests of your memory, your thinking your mood, and your movements. These are 
like IQ tests and will not cause any harm to you or your family. These are tests that 
will involve you telling me things, pointing out things and moving your hands.   
 An examiner will test how well you can feel vibration in your ankle using a Tuning 
Fork  
 A checklist that will record the number, type and severity of all injuries 
 
    
Whenever possible, you will be interviewed in privacy in order to complete the questionnaire 
and to conduct the tests. Any personal information will be kept confidential. 
 
5. Risks and discomforts of the research    
There are no risks when completing the questionnaires. However testing will be stopped if 
you as the participant request it and can be continued at a later time or not at all.  If you are 
uncomfortable about any aspect of the testing, intervention or treatment will be made 
available from a trained clinical staff member.  
 
6. Expected benefits to you and others 
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This study will try to find out whether you have been affected negatively because of using 
and/or coming into close contact with pesticides in your farming activities and if you have 
been affected, you will be provided with information about pesticides and referred to your 
nearest hospital or clinic if necessary.  It is important that you and adult members of your 
family attend all of these testing sessions to determine the effects of pesticide exposure on 
your health.  
 
7. Costs to you resulting from participation in the study 
You will not be paid or have to pay for taking part in the study.  You will be provided with 
lunch or tea if you have to spend a long time with us in the study. 
 
8. Confidentiality of information collected 
You will not be personally identified in any reports on this study.  The records will be kept 
confidential to the extent provided by law.   
 
9. Documentation of the consent 
A copy of this document will be kept together with my research records on this study.   
 
10. Contact person 
You may contact the following persons for answers to further questions about the research, 
your rights, or any injury you may feel relates to the study. 
 
Professor Marc Blochman (Chairperson of the Research Ethics Committee) 
Telephone: 021 406 6492 
 
Name of researcher: Ms. Zelda Holtman (Student and researcher)      
Telephone: 021 406 6842 
Fax: 021 406 6163 
Email: Zelda.Holtman@uct.ac.za 
 
Name of Principal Investigator:  Professor Leslie London 
Telephone: 021 406 6524 
Fax: 021 406 6163 
Email: Leslie.London@uct.ac.za 
 
Name of Principal Co-investigator:  Dr Aqiel Dalvie 
Telephone: 021 406 6610 
Fax: 021 406 6163 
Email: Aqiel.Dalvie@uct.ac.za 
 
 
11. Voluntary nature of participation 
Your participation in this project is entirely voluntary. You must decide whether you want to 
participate or not, without feeling obligated to anyone. You will not suffer any discrimination 
from the extension officers or the health services if you decide you do not want to participate. 
Even if you start participating in the study, you can always change your mind later and 
withdraw from the study. 
 
 
Consent of the participant 
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Head of household 
I have read the information given above.  I understand the meaning of this information.  I, 
Mr./Ms/Mrs ________________________have offered to answer any questions concerning 
the study.  I hereby consent to participate in the study. 
 
I understand that an adult member of my family will also be asked to participate in the study 
and I Mr./Ms/Mrs ________________________ as head of my household hereby give my 
consent for my wife/partner/adult daughter/adult son to be approached to participate in the 
study. 
 
 
 
____________________________  _______________________   
Printed name of participant  signature    Date 
(Head of household) 
 
 
 
____________________________  _______________________    
Interviewer (print)    signature    Date 
 
 
 
 
____________________________  _______________________   
Printed name of witness             signature    Date 
(if participant is unable to read 
and write) 
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 APPENDIX D: Supplementary Tables to Journal 
Manuscript 
 
Table 9: Description of exposure information 
Variables N (%) Median (IQR) 
Current Job 
Farm worker 
Total    283 (94)   
Pesticide Applicator 160 (53.2)    
General Worker 6 (2.0)    
Infield Non-applicator 117 (38.9)     
Non-farm worker 
Total    18 (6)   
Industry 1 (0.3)    
Other 9 (3.0)    
Pensioner 6 (2.0)    
Unemployed 2 (0.7)    
Pesticide Exposure 
Number of job years     8 (4-14) 
Pesticide exp. 157 (52.3)    
No Pesticide exp. 143 (47.8)     
Applicator status 
Past and current Applicators (All pesticides) Non-applicators 141 (46.8)     
Applicators 160 (53.2)    
Current Applicators (All pesticides) Non-applicators 152 (50.7)    
Applicators 148 (49.3)    
OP Applicators Non-OP Applicator 234 (77.7)    
OP Applicator 67 (22.3)     
Past poisoning 
Diagnosed poisoned cases 22 (11.5)     
Non-cases 170 (88.5)     
All pesticide exposure 
Long term exposure days (8 hr days)   543.8 (71.1-1460.4) 
Jem days weighted by activity   369.3 (52.3-1022.3) 
Jem days weighted by activity & crop type    4182.6 (544.8-
144452.1) 
Jem days weighted by activity & crop type per annum     428.0 (83.8-1348.7) 
OP pesticide exposure 
Long term exposure days (8 hr days)   308.0 (45.0-953.4)  
Jem days weighted by activity   215. 6 (31.5-667.4)  
Jem days weighted by activity & crop type    1950.9 (339.0-7545.9)  
Jem days weighted by activity & crop type per annum     143.3 (36.1-732.1) 
Type of crop farming 
Any Combination 66 (21.9)   
Citrus 68 (22.6)   
Deciduous Fruit 79 (26.3)   
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Variables N (%) Median (IQR) 
Grapes 20 (6.6)   
Vegetables 50 (16.6)   
Other Crops 13 (4.3)   
No crops 5 (1.6)   
 
 
Table 10:Demographic,Llifestyle and Socioeconomic factors by the different 
Neurobehavioural Outcomes 
  Digit Span Forward Digit Span Backward Digit Span WAIS Vibration Sensitivity 
N Median N Median N Median N Median 
Demographic Variables 
Gender Female 97 6 (5-7) 97 4 (3-4) 97 7 (6-8) 97 12.50 (9-15) 
Male 204 6 (4.50-7) 204 3 (2-4) 204 6 (6-8) 204 13.50 (10-17.25) 
Language Afrikaans 262 6 (5-7) 262 3 (2-4) 262 6 (6-8) 259 12.50 (9-17) 
Xhosa 31 5 (4-7) 31 3 (2-4) 31 6 (5-8) 30 14.50 (12.00-16.50) 
Sotho 8 5.5 (4-7) 8 3.5 (3-6) 8 7 (5-9) 8 13.25 (12.25-14.5) 
Education ≤9 years education 197 6 (4-7) 197 3 (2-4) 197 6 (5-8) 194 13 (9.50-16.50) 
>9 years education 104 6 (5-8) 104 4 (3-5) 104 7 (6-9) 103 13 (10-17) 
District Overberg 69 6 (5-7) 69 3 (2-4) 69 6 (6-8) 69 13 (9.50-16) 
Winelands 148 6 (5-7.50) 148 4 (3-4) 148 6 (6-8) 145 12.50 (9-16.50) 
West Coast 84 6 (4-8) 84 3 (2-4) 84  6 (5-8) 83 14 (10-17.50) 
Crop code Any Combination  66 6 (5-8) 66 4 (3-4) 66 7 (6-8) 64 13 (8.50-17.75) 
Citrus Fruits  68 6 (4-8) 68 3 (2-4) 68 6 (5-8) 67 14 (10-17) 
Deciduous Fruits  79 6 (4-7) 79 3 (2-4) 79 6 (6-8) 79 12 (8-16) 
Grapes  20 5 (5-7) 20 4 (2.5-4) 20 6 (6-7.5) 20 12.25 (9.25-15.75) 
No crops 5 5 (3-6) 5 3 (3-3) 5 6 (5-6) 5 13 (9-14) 
Other  13 7 (5-10) 13 4 (4-5) 13 8 (7-11) 13 16 (11.5-17) 
Vegetables 50 6 (5-8) 50 4 (2-4) 50 7 (6-8) 49 13 (10-16.5) 
Lifestyle Factors 
CAGE Score Not Problem alcohol 
users (≤2) 
162 6 (5-7) 162 4 (2-4) 162 7 (6-8) 159 13 (9.5-16.5) 
Problem alcohol 
users (≥2) 
139 6 (5-7) 139 3 (2-4) 139 6 (5-8) 138 12.25 (9-17) 
Current 
Alcohol 
Consumption 
YES 188 6 (5-7) 188 3 (2-4) 188 6 (6-8) 186 12.5 (9.5-16.5) 
NO 113 6 (5-7) 113 4 (2-4) 113 7 (6-8) 111 13.5 (9.5-17) 
Smoking 
Habits 
Non-current Smoker 100 6 (5-7) 100 3.5 (2-4) 100 6.5 (6-8) 100 12 (9.5-16) 
Current Smoker 201 6 (5-7) 201 3 (2-4) 201 6 (5-8) 197 13.5 (9-17) 
Previous 
Head 
Injuries 
Reported Head Injury 35 7 (5-8) 35 3 (3-4) 35 7 (6-8) 33 15.5 (12-20) 
No-reported Injury 266 6 (5-7) 266 3 (2-4) 266 6 (6-8) 264 12.5 (9.25-16.5) 
Reported Illness 5 5 (5-5) 5 4 (3-4) 5 6 (5-6) 5 17 (14.5-20) 
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  Digit Span Forward Digit Span Backward Digit Span WAIS Vibration Sensitivity 
N Median N Median N Median N Median 
Psychiatric 
Illness 
Non-reported Illness 296 6 (5-7) 296 3 (2-4) 296 6 (6-8) 292 13 (9.5-16.5) 
Socioeconomic Status 
Owns >3 items 264 6 (5-8) 264 3 (2-4) 264 6 (6-8) 261 13 (9-16.5) 
Owns ≤3 items 37 6 (5-8) 37 4 (2-4) 37 6 (6-8) 36 14.5 (11.5-17.75) 
No Grant 201 6 (5-8) 201 4 (2-4) 201 6 (6-8) 198 13 (9.5-16.5) 
Grant 100 6 (5-7) 100 3 (2-4) 100 6 (6-8) 99 12.5 (9.5-17) 
Not Hungry 258 6 (5-8) 258 3 (2-4) 258 6 (6-8) 255 13 (9.5-17) 
Hungry occasionally 43 6 (5-7) 43 4 (2-5) 43 7 (5-8) 42 13.5 (9.5-16.5) 
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Table 11: Demographic, Lifestyle and Socioeconomic Information by Genetic Polymorphisms 
  
GSTT GSTM NAT PON1_55 PON1_192 
NULL YES NULL YES GG GA AA TT TA AA GG GA/AG AA 
Demographic Variables 
Gender F 3 (3.09) 94 (96.91) 21 (21.65) 76 (78.35) 85 (87.63) 11 (11.34) 1 (1.03) 65 (67.01) 30 (30.93) 2 (2.06) 47 (48.45) 37 (38.14) 13 (13.40) 
  M 1 (0.49) 203 (99.51) 27 (13.24) 177 (86.76) 187 (91.67) 16 (7.84) 1 (0.49) 144 (70.59) 54 (26.47) 6 (2.94) 91 (44.61) 93 (45.59) 20 (9.80) 
Age (years) 
46.50  
(33.00-50.50) 
39.00  
(30.00-48.00) 
38 (32-44) 40 (30-49) 39 (30-48) 43 (33-53) 39 (39-39) 40 (30-49) 
37.50  
(30.50-44) 
41.50  
(30.00-50.00) 
38.50  
(29.00-46.00) 
40 (31-48) 40 (29-500) 
Language 
A 3 (1.15) 259 (98.85) 40 (15.27) 222 (84.73) 234 (89.31) 26 (9.92) 2 (0.76) 182 (69.47) 73 (27.86) 7 (2.67) 123 (46.95) 110 (41.98) 29 (11.07) 
X 0 31 (100) 6 (19.35) 25 (80.65) 30 (96.77) 1 (3.23) 0 22 (70.97) 8 (25.81) 1 (3.23) 12 (38.71) 16 (51.61) 3 (9.68) 
S 1 (12.50) 7 (87.50) 2 (25) 6 (75) 8 (100) 0 0 5 (62.5) 3 (37.50) 0 3 (37.5) 4 (50) 1 (12.5) 
Education 
(Years) 
≤9  1 (0.96) 103 (99.04) 17 (16.35) 87 (83.65) 93 (89.42) 10 (9.62) 1 (0.96) 66 (63.46) 35 (33.65) 3 (2.88) -5481.00% 37 (35.58) 10 (9.62) 
>9  3 (1.52) 194 (98.48) 31 (15.74) 166 (84.26) 179 (90.86) 17 (8.63) 1 (0.51) 143 (72.59) 49 (24.87) 5 (2.54) 81 (41.12) 93 (47.21) 23 (11.68) 
District 
O 2 (2.90) 67 (97.10) 15 (21.74) 54 (78.26) 62 (89.86) 7 (10.14) 0 53 (76.81) 15 (21.74) 1 (1.45) 36 (52.17) 24 (34.78) 9 (13.04) 
W 2 (1.35) 146 (98.65) 28 (18.92) 120 (81.08) 128 (86.49) 18 (12.16) 2 (1.35) 86 (58.11) 57 (38.51) 5 (3.38) 64 (43.24) 65 (43.92) 19 (12.84) 
WC 0 84 (100) 5 (5.95) 79 (94.05) 82 (97.62) 2 (2.38) 0 70 (83.33) 12 (14.29) 2 (2.38) 38 (45.24) 41 (48.81) 5 (5.95) 
Crop code 
Cb 0 66 (100) 14 (21.21) 52 (78.79) 59 (89.39) 6 (9.09) 1 (1.52) 41 (62.12) 24 (36.36) 1 (1.52) 31 (46.97) 28 (42.42) 7 (10.61) 
CF 0 68 (100) 5 (7.35) 63 (92.65) 66 (97.06) 2 (2.94) 0 58 (85.29) 8 (11.76) 2 (2.94) 30 (44.12) 33 (48.53) 5 (7.35) 
DF 1 (1.27) 78 (98.73) 21 (26.58) 58 (73.42) 67 (84.81) 12 (15.19) 0 61 (77.22) 16 (20.25) 2 (2.53) 35 (44.3) 32 (40.51) 12 (15.19) 
G 2 (10) 18 (90) 3 (15) 17 (85) 17 (85) 3 (15) 0 6 (80) 12 (60) 2 (10) 4 (20) 13 (65) 3 (15) 
N 0 5 (100) 1 (20) 4 (80) 5 (100) 0 0 4 (61.54) 1 (20) 0 3 (60) 2 (40) 0 
O 0 13 (100) 0 13 (100) 12 (92.31) 1 (7.69) 0 8 (61.54) 5 (38.46) 0 6 (46.15) 6 (46.15) 1 (7.69) 
V 1 (2) 49 (98) 4 (8) 46 (92) 46 (92) 3 (6) 1 (2) 31 (62) 18 (36) 1 (2) 29 (58) 16 (32) 5 (10) 
Height 
1.57  
(1.52-1.63) 
1.64  
(1.58-1.71) 
1.64  
(1.57-1.70) 
1.64  
(1.58-1.71) 
1.64  
(1.58-1.71) 
1.61  
(1.56-1.68) 
1.55  
(1.53 - 1.57) 
1.63  
(1.58-1.71) 
1.64  
(1.57-1.71) 
1.68  
(1.64-1.69) 
1.63  
(1.57-1.71) 
1.64 (1.59-1.71) 1.64 (1.57-1.68) 
Weight 73.00  (61.00-82.50) 
62.00  
(55.00-73.00) 
65.00  
(58.00-77.50) 
62.00  
(55.00-71.00) 
63 (56-74) 
60.00  
(54.00-71) 
61 (42-80) 
61.50  
(55.00-75.00) 
63.00  
(55.00-70.00) 
58.50  
(53.00-62.50) 
64 (56-75) 61 (55-70) 60 (51-70) 
BMI 31.55  
(25.00-33.44) 
22.77  
(20.05-27.36) 
23.78 
(20.42-30.09) 
22.77  
(19.79-27.06) 
22.83  
(20.05-27.46) 
22.43 
(21.22-25.39) 
25.61  
(17.04-34.17) 
22.87  
(20.07-27.40) 
22.68  
(19.94-28.25) 
21.13  
(18.78-23.36) 
22.96  
(20.76-28.37) 
22.55  
(19.66-26.67) 
22.04  
(18.59-26.35) 
Lifestyle Factors  
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GSTT GSTM NAT PON1_55 PON1_192 
NULL YES NULL YES GG GA AA TT TA AA GG GA/AG AA 
CAGE 
Score 
No 
case 
3 (1.85) 159 (98.15) 27 (16.67) 135 (83.33) 147 (90.74) 15 (9.26) 0 106 (65.43) 54 (33.33) 2 (1.23) 74 (45.68) 73 (45.06) 15 (9.26) 
case 1 (0.71) 138 (99.28) 21 (15.11) 118 (84.89) 125 (89.93) 12 (8.63) 2 (1.44) 103 (74.10) 30 (21.58) 6 (4.32) 64 (46.04) 57 (41.01) 18 (12.95) 
Current 
Alcohol 
Consumptio
n 
Yes 2 (1.06) 186 (98.94) 35 (18.62) 153 (81.38) 169 (89.98) 17 (9.04) 2 (1.06) 132 (70.21) 50 (26.60) 6 (3.19) 86 (45.74) 79 (42.02) 23 (12.23) 
No 2 (1.77) 111 (98.23) 13 (11.50) 100 (88.50) 103 (91.15) 10 (8.85) 0 77 (68.14) 34 (30.09) 2 (1.77) 52 (46.02) 51 (45.13) 10 (8.85) 
Current 
smoking 
Habits 
Non 3 (3) 97 (97) 14 (14) 86 (86) 88 (88) 12 912) 0 70 (70) 28 (18) 2 (2) 46 (46) 45 (45) 9 (9) 
Yes 1 (0.5) 200 (99.5) 34 (16.92) 167 (83.08) 184 (91.54) 15 (7.46) 2 (1) 139 (69.15) 56 (27.86) 6 (2.99) 92 (45.77) 85 (42.29) 24 (11.94) 
Previous 
Head 
Injuries 
Yes 0 35 (100) 3 (8.57) 32 (91.43) 33 (94.29) 2 (5.71) 0 28 (80) 6 (17.14) 1 (2.86) 13 (37.14) 20 (57.14) 2 (5.71) 
No 4 (1.50) 262 (98.5) 45 (16.92) 221 (83.08) 239 (89.85) 25 (9.4) 2 (0.75) 181 (68.05) 78 (29.32) 7 (2.63) 125 (46.99) 110 (41.25) 31 (11.65) 
Psychiatric 
Illness 
Yes 0 5 (100) 1 (20) 4 (80) 4 (80) 1 (20) 0 5 (100) 0 0 4 (80) 0 1 (20) 
No 4 (1.35) 292 (98.65) 47 (15.88) 249 (84.12) 268 (90.54) 26 (8.78) 2 (0.68) 204 (68.92) 84 (28.38) 8 (2.7) 134 (45.27) 130 (43.92) 32 (10.81) 
Socioeconomic Status  
Owns >3 items 2 (0.76) 262 (99.24) 41 (15.53) 223 (84.47) 240 (90.91) 22 (8.33) 2 (0.76) 181 (68.56) 77 (29.17) 6 (2.27) 120 (45.45) 115 (43.56) 29 (10.98) 
Owns ≤3 items 2 (5.41) 35 (94.59) 7 (18.92) 30 (81.08) 32 (86.49) 5 (13.51) 0 28 (75.68) 7 (18.92) 2 (5.41) 18 (48.65) 15 (40.54) 4 (10.81) 
No Grant 2 (1) 199 (99) 30 (14.93) 171 (85.07) 180 (89.55) 19 (9.45) 2 (1) 139 (69.15) 55 (27.36) 7 (3.48) 92 (45.77) 86 (42.79) 23 (11.44) 
Grant 2 (2) 98 (98) 18 (18) 82 (82) 92 (92) 8 (8) 0 70 (70) 29 (29) 1 (1) 46 (46) 44 (44) 10 (10) 
Not Hungry 3 (1.16) 255 (98.84) 40 (15.50) 218 (84.50) 231 (89.53) 25 (9.69) 2 (0.78) 178 (68.99) 72 (27.91) 8 (3.10) 116 (44.96) 116 (44.96) 26 (10.08) 
Hungry 
occasionally 
1 (2.33) 42 (97.67) 8 (18.60) 35 (84.05) 41 (95.35) 2 (4.65) 0 31 (72.09) 12 (27.91) 0 22 (51.16) 14 (32.56) 7 (16.28) 
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 APPENDIX E: Instructions to Authors 
 
1. INSTRUCTIONS TO AUTHORS 
Who We Are 
What We Publish 
About Your Manuscript 
Manuscript Preparation 
EHP Style 
Manuscript Submission 
Publication Sequence 
Types of References (additional examples) 
Abbreviations 
2. WHO WE ARE 
Environmental Health Perspectives (EHP) is a monthly open-access journal that publishes peer-
reviewed research and news concerning human health and the environment. One of the 
overarching principles of the journal is to provide a forum for the objective and balanced 
presentation of scientifically credible information. Although EHP is sponsored by the National 
Institute of Environmental Health Sciences (NIEHS), its editorial policies are independent of the 
institute. 
In 2004 EHP became an open-access journal. All content published since the beginning of the 
journal in 1972 is available free online at http://www.ehponline.org/ 
andhttp://www.ncbi.nlm.nih.gov/pmc/journals/253/. EHP is committed to promoting the discussion 
and exchange of information internationally, as described in detail 
athttp://www.ehponline.org/international/. 
  
3. WHAT WE PUBLISH 
The environmental health sciences include many fields of study and increasingly comprise multi-
disciplinary research areas. EHP publishes articles from a wide range of scientific disciplines 
encompassing mechanistic research, experimental and observational human studies, 
and in vitro and in vivo animal research with a clear relationship to human health effects. Studies 
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involving exposure science, climate change, ecologic issues, or effects on wildlife populations are 
welcome, but the relevance of the findings to human health should be made clear. EHPalso 
addresses ethical, legal, social, and policy issues related to environmental public health. Because 
children are uniquely sensitive to their environments, EHP devotes a research section specifically 
to issues surrounding children’s environmental health. 
EHP provides additional information on environmental health issues through its News and 
Editorials. Although EHP welcomes ideas for News and Editorials, the journal does not accept 
unsolicited manuscripts of these types. Please contact the Editor-in-Chief for further information. 
  
4. ABOUT YOUR MANUSCRIPT 
 
All papers submitted to EHP are evaluated by a group of consulting editors to determine whether 
the topic is within the scope of the journal and to evaluate adherence to word limits and journal 
format. Papers also are assessed for originality, scientific quality, environmental health 
significance, clarity of presentation, and conciseness. Before papers are sent for peer review, they 
are screened for possible plagiarism (see Scientific Integrity below), and authors must submit a 
Competing Financial Interests Declaration form on behalf of all authors (see Competing Financial 
Interests below). Papers selected for review are assigned to an Associate Editor, who identifies 
reviewers and makes recommendations to the Editor-in-Chief. Members of the Editorial Review 
Board serve as a pool of potential reviewers of papers. Both the Board of Associate Editors and 
the Editorial Review Board are composed of leading scientists from all segments of the 
environmental health sciences. The overall acceptance rate of papers submitted to the journal is 
approximately 15%. 
 
4.1.1. Types of Manuscripts 
 
Manuscripts in the categories below are considered for publication. All manuscripts are peer 
reviewed except Correspondence. See Article Length below for details concerning word limits. 
Correspondence (≤ 750 words) should address specific scientific issues or questions raised by 
Research or News Articles published in the journal within the previous 6 months. Authors of papers 
cited in Correspondence will be given the opportunity to respond. Letters addressing issues raised 
in previously published letters are discouraged. Correspondence may include a brief table or small 
figure if it is critical to the discussion. New data must not be included. Authors may include data 
from or redrawing of previously published materials as long as the work is cited and written 
permission from the original authors and/or publishers has been granted for republication in both 
printed and electronic form. Each figure is considered equivalent to 250 words toward the total 
word count. Correspondence that cites abstracts or unpublished observations is not acceptable 
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and will not be published. Letters that are highly polemic or personal in nature will not be published. 
Correspondence is not peer reviewed and is published at the discretion of the EHP editors. 
Conclusions and opinions expressed by the authors do not necessarily reflect the policies of EHP. 
 
Commentaries (≤ 5,000 words) present information and personal insight on a particular topic. 
Commentaries should not be extended critiques of single articles appearing in EHP or elsewhere. 
Factual data should be included to substantiate arguments. EHP reserves the right to reject 
Commentaries without review if they are perceived as being too polemic or personal in 
nature. EHP also reserves the right to propose that Commentaries be reviewed as one side of a 
point/counterpoint debate. Assuming the original author agrees, EHP will ask another author to 
address the opposite side of an argument. If both papers are accepted, EHP will publish them 
together. Manuscripts on ethical, legal, social, or policy issues may also be accepted in this 
category. 
 
Research Articles (≤ 7,000 words) report original scientific research and discovery. Research 
Articles may come from any field of scientific research relevant to the study of human health and 
the environment. 
 
Substantive Reviews (≤ 10,000 words) provide an overview, integration of information, and critical 
analysis of a particular field of research or theme related to environmental health sciences. 
Previous research should be comprehensively reviewed regardless of whether the findings are 
consistent with expectations or the review authors’ hypotheses. It is appropriate for authors to 
discuss the strengths and weaknesses of individual studies, focus on high-quality studies that add 
to the weight of the evidence on the topic under review, identify information gaps, and make recom-
mendations for future research. Lengthy historical perspectives generally are not appropriate. 
 
Quantitative Reviews and Meta-Analyses (≤ 10,000 words) present, contrast, and (when 
appropriate) combine data across studies to address a specific study question related to environ-
mental health. Inclusion criteria and strategies used to search the literature should be explicitly 
described, along with analytic methods used to evaluate or combine data. The potential for 
publication bias and heterogeneity among studies should be investigated, and graphical displays 
of data contributed by individual studies are encouraged. The strengths and weaknesses of 
individual studies and potential causes of discordant findings among studies also should be 
discussed. As with Substantive Reviews, authors should integrate and critically analyze 
information from previous research, identify information gaps, and make recommendations for 
future research. 
Reviews Based on Meetings or Conferences (≤ 10,000 words) should review the state of the 
science for a particular area, identify research gaps and needs, and explain how the outcome of 
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the meeting or conference addresses those gaps and needs. These reviews should focus on the 
science or theme but not on the conference or meeting itself. De novo data, participant lists, 
dialogue of workgroups or committees, and discussion of the internal organization of the meeting 
are not allowed. These papers should be submitted to EHP no more than 1 year after the meeting 
or conference takes place. Prospective authors should consult with the Editor-in-Chief before 
submitting a review based on a meeting or conference. 
 
Brief Communications (≤ 4,000 words) are short scholarly reports that provide timely information 
of interest to the broad environmental health community. They may be used to highlight the 
importance of new environmental health programs or agencies or the advantages of new research 
approaches in the context of knowledge gaps; or to raise awareness of and make 
recommendations for addressing contemporary or emerging environmental health problems. A 
Brief Communication may take the form of a statement from an organization or group concerning 
the need for action on an environmental health issue (typically with recommendations). Authors 
should contact the Editor-in-Chief in advance for permission to submit. Brief Communications are 
reviewed internally for relevance, importance, and clarity, and are published without Advance 
Publication in the Perspectives section of EHP. They are assigned a DOI number and indexed in 
PubMed/MEDLINE. Formatting requirements, including references and any tables or figures, are 
consistent with those for EHP Research Articles, with the exception of the abstract, which must be 
unstructured (without subheadings) and ≤ 200 words. In addition, Supplemental Material is not 
allowed. 
4.1.2.  
4.1.3. Originality of Submission 
 
Contributions submitted to EHP must be original works of the author(s) and must not have been 
previously published in print or online or simultaneously submitted to another publication. 
Previously published material (e.g., figures, tables) may be included in Commentaries and 
Reviews, assuming the original authors have given permission to reproduce the material and all 
copyright issues have been resolved. For original Research Articles, previously published 
schemata or illustrative figures are acceptable with the proper attribution and permission. Text or 
narrative from guidance documents, technical reports, and position papers by various government 
and nongovernmental organizations may be considered if they include new information.EHP will 
consider papers from dissertations that have been published in their entirety by a university in 
partial fulfillment of a degree. Manuscripts presented at a scientific meeting but not published in 
full or under review for publication elsewhere also will be considered. As indicated in Uniform 
Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for 
Biomedical Publication [International Committee of Medical Journal Editors 
(http://www.icmje.org/urm_full.pdf)], it is the responsibility of the author to make a full statement to 
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the editor concerning materials in a manuscript that might be considered redundant or duplicative. 
For additional clarification, please contact the Editor-in-Chief. 
4.1.4.  
4.1.5. Scientific Integrity 
 
EHP requires assurances that animals used in a study have been treated humanely and with 
regard for the alleviation of suffering. Research involving humans must have been conducted 
according to the Common Rule 
(http://ori.dhhs.gov/education/products/ucla/chapter2/page04b.htm). Research involving humans 
also must be approved by an appropriate institutional review board and comply with all relevant 
national, state, and local regulations. For research conducted outside the United States and thus 
exempt from U.S. federal regulations, authors must perform the research in accordance with 
principles of the Declaration of Helsinki (http://www.wma.net/en/30publications/10policies/b3/). 
Approval and compliance with research requirements regarding human subjects must be noted, 
and information regarding informed consent procedures must be described in the “Methods” 
section of manuscripts concerning human subjects research. 
 
EHP is sometimes confronted with issues regarding potential research misconduct, such as 
plagiarism or data fabrication. Authors should be aware that all papers submitted to EHP are 
screened routinely for plagiarism, defined as “the appropriation of another person’s ideas, 
processes, results, or words without giving appropriate credit” (American Medical Association. 
2007. AMA Manual of Style: A Guide for Authors and Editors, 10th edition. New York:Oxford 
University Press). Instances of documented plagiarism and allegations of data fabrication will be 
brought to the attention of the authors’ host institutions. Documented cases of plagiarism or data 
fabrication could lead to a 3-year ban on future publication in EHP by the authors, a published 
Expression of Concern, and/or retraction of the paper. 
 
4.1.6. Dual-Use Research 
 
EHP anticipates receiving submissions on research that, based on current understanding, can be 
reasonably anticipated to provide knowledge, products, or technologies that could be directly mis-
applied by others to pose a threat to public health and safety, agriculture, plants, animals, or the 
environment (also known as dual-use research). Papers flagged for dual-use issues 
by EHP editors will undergo an additional level of review concerning the implications to society of 
publishing such a paper, and EHP reserves the right to seek expert advice in such cases. Authors 
should be aware that EHP could determine that the risks to public health and safety of publishing 
the paper outweigh the benefits of publishing, even if the paper has otherwise been deemed 
acceptable for publication. 
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4.1.7.  
4.1.8. Suggested Guidelines 
 
EHP endorses the ARRIVE guidelines for reporting results from animal studies 
(http://www.nc3rs.org.uk/ARRIVE). We encourage authors to review these guidelines when 
designing their studies and to use them in writing papers for submission to EHP, and we encourage 
our Associate Editors and peer reviewers to keep in mind the principles articulated in the ARRIVE 
guidelines when evaluating papers involving animal research. EHP encourages authors of Review 
articles to follow recommendations for transparent reporting of systematic reviews as described in 
the PRISMA Statement (http://www.prisma-statement.org). Authors performing microarray 
experiments should follow the Minimum Information About a Microarray Experiment (MIAME) 
guidelines developed by the Microarray Gene Expression Data (MGED) Society 
(http://www.mged.org/miame). 
4.1.9.  
4.1.10. Competing Financial Interests 
 
EHP has a policy of full disclosure. Authors must declare all actual or potential competing financial 
interests involving people or organizations that might reasonably be perceived as relevant. 
Disclosure of competing interests does not imply that the information in the article is questionable 
or that conclusions are biased. Decisions to publish or reject an article will not be based solely on 
a declaration of a competing interest. 
 
For each manuscript, authors must submit a Competing Financial Interests Declaration (CFID) 
form (available at http://ehp.niehs.nih.gov/wp-content/uploads/2012/09/EHP-CFI-form-blank.pdf). 
Papers will not be processed for peer review unless a CFID form has been submitted. Authors of 
Correspondence and Editorials also are required to submit a CFID form. 
Authors must disclose all actual or potential competing financial interests occurring within the last 
3 years, including but not limited to 
 Grant support 
 Employment (past, present, or firm offer of future) 
 Patents (pending or applied) 
 Payment for expert witness or testimony 
 Personal financial interests by the authors, immediate family members, or institutional affiliations 
that may gain or lose financially through publication of the article 
 Forms of compensation, including travel funding, consultancies, board positions, patent and royalty 
arrangements, stock shares, or bonds. Diversified mutual funds or investment trusts do not 
constitute a competing financial interest. Authors should carefully examine the wording of 
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documents such as grants and contracts to determine whether there might be an actual or potential 
competing interest. 
 
Employment of any author by a for-profit or nonprofit foundation or advocacy group or work as a 
consultant also must be indicated on the CFID form. 
As a condition of review and publication, authors must further certify that their freedom to design, 
conduct, interpret, and publish research is not compromised by any controlling sponsor. 
A statement of disclosure consistent with the information contained in the CFID form must be 
included in the Acknowledgments section of the manuscript submitted to the journal. If there are 
no actual or potential competing financial interests, this must be indicated: for example, “The 
authors declare they have no actual or potential competing financial interests.” 
Editors and reviewers also must disclose to the Editor-in-Chief any actual or potential competing 
interests, both financial and nonfinancial, that have occurred within the last 3 years and could 
reasonably be perceived as relevant. Competing nonfinancial interests include former or current 
mentor–student relationships, faculty appointments in the same department or organization, 
familial relationships, service on advisory boards that oversee the research under review, 
collaborations, or membership in organizations that hold ideological views that are contradictory to 
the theme or topic under review. 
EHP relies on the integrity of all authors to provide accurate disclosure statements. However, 
authors can expect scrutiny of their statements by the editors, reviewers, and readership. Alleged 
inaccuracies of declared competing interests should be addressed to the Editor-in-Chief. EHP will 
impose a 3-year ban on publication in EHP by any authors found to have willfully failed to disclose 
a competing financial interest. A paper may also be retracted or an Expression of Concern 
published and appended to the article. 
  
5. MANUSCRIPT PREPARATION 
5.1.1.  
5.1.2. Article Length 
 
All words in the main text, title pages, abstract, tables, and references count toward EHP word 
limits. In addition, each figure is counted as 250 additional words. Manuscripts that do not conform 
to the word limits may be returned to the author(s) for revision before the review process is initiated. 
Depending on the topic and potential impact of a paper, the Editor-in-Chief reserves the right to 
waive word limits. Authors may place some types of information, such as lengthy descriptions of 
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previously published methods, into Supplemental Material; however, these methods must be 
described briefly in the text of the paper. Information included in Supplemental Material does not 
count toward the word limit. The judicious use of references also may help meet the following word 
limits: 
 
 Correspondence: ≤ 750 words 
 Commentaries: ≤ 5,000 words 
 Research Articles: ≤ 7,000 words 
 Substantive Reviews: ≤ 10,000 words 
 Quantitative Reviews and Meta-Analyses: ≤ 10,000 words 
 Reviews Based on Meetings or Conferences: ≤ 10,000 words. 
5.1.3.  
5.1.4. Parts of a Manuscript 
 
Title Pages 
The title pages should include the following items in the order shown, beginning on the first page 
of the manuscript: 
 Manuscript title, not to exceed 20 words [Titles should describe the research or topic of the paper 
but not summarize results or conclusions; titles generally should not contain abbreviations or 
numerical values, with the exception of abbreviated study names (e.g., NHANES)] 
 Names of the authors spelled out in full 
 Affiliations of all authors (department, institution, city, state/province, and country) 
 Name of and contact information for corresponding author to whom page proofs should be sent, 
including complete address for express mail service, telephone number, and e-mail address 
 A short running title, not to exceed 50 characters and spaces 
 Acknowledgments, including grant information 
 A competing financial interests declaration. 
 
Abstract 
 
All papers must include a structured abstract of ≤ 250 words, which should not contain references. 
No information should be reported in the abstract that does not appear in the text of the manuscript. 
In general we recommend that authors indicate study names or sources of data that are integral 
to the study in the title or abstract. Conclusions should mention the relevance of the work to 
environmental health science. Headings to be used in the structured abstracts vary by article type 
as described below: 
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 Commentaries: Background, Objectives, Discussion, Conclusions 
 Research Articles, Quantitative Reviews, and Meta-Analyses: Background, Objectives, Methods, 
Results, Conclusions 
 Substantive Reviews and Reviews Based on Meetings or Conferences: Background, Objectives, 
Methods, Discussion, Conclusions. 
 
Main Text 
The organization of the text varies by article type and roughly reflects the structure of the abstract: 
 Commentaries: Introduction (comprising the Background and Objectives stated in the abstract), 
Discussion, Conclusions 
 Research Articles: Introduction (comprising the Background and Objectives stated in the abstract), 
Methods, Results, Discussion, Conclusions 
 Reviews: Introduction (comprising the Background and Objectives stated in the abstract), Methods 
(including data sources), Results (as appropriate), Discussion, Conclusions. 
Concise subheadings (≤ 8 words each) may be used to designate major topics within each of these 
sections. 
References, Tables, Figures, and Supplemental Material 
The following items should be provided after the main text of the paper in this order: References, 
Tables, Figure Legends. The References, Tables, and Figure Legends must each begin on a new 
page of the manuscript. Figures and Supplemental Material should be provided as separate files. 
Additional information concerning each of these sections is provided in “EHP Style” below. 
5.1.5.  
5.1.6. Conformance to EHP Style Guidelines 
 
Manuscripts submitted to EHP must conform to all EHP style requirements as described in 
“EHP Style” below. Authors should take special note of requirements for citations and references, 
figures, and tables. Manuscripts that do not conform to style requirements may be returned to the 
authors for modification before the initiation of the peer-review process. This step will cause a 
significant delay in the review and possible acceptance of the manuscript. All manuscripts must be 
submitted to EHP in English. 
5.1.7.  
5.1.8. Manuscript Formatting 
 
Manuscript pages must be numbered consecutively, beginning with the title page, and lines should 
be numbered in the original submission and all subsequent revisions. The manuscript must be 
prepared using Times New Roman font at 12-point size. The manuscript must be double-spaced, 
with all margins set at 1 inch. 
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For additional information, see the AMA Manual of Style: A Guide for Authors and Editors, 10th 
edition (American Medical Association 2007). A basic source for spelling is Merriam-Webster’s 
Collegiate Dictionary, 11th edition. 
Resources for assistance with research, presentation, and language are available from the 
following organizations: 
 International Committee of Medical Journal Editors [Uniform Requirements for Manuscripts 
Submitted to Biomedical Journals: Writing and Editing for Biomedical 
Publication(http://www.icmje.org/)] 
 AuthorAID (http://www.authoraid.info/). 
  
6. EHP STYLE 
6.1.1.  
6.1.2. Plain Language 
 
EHP covers all disciplines engaged in the broad field of environmental health sciences. Therefore, 
authors should write in a clear and simple manner, in the active voice, and avoid unnecessary 
jargon, so the article is understandable to readers in other disciplines and to those whose first 
language is not English. In deference to the breadth of the journal’s readership, please define 
terms that may not be universally recognized among all environmental health scientists. 
Clearly define all outcomes, exposures, predictors, confounders, and covariates, and describe the 
methods or assays used to characterize study data. Results should be presented in a clear and 
unambiguous manner. Comparison groups or reference conditions should be clearly indicated 
when reporting measures of association or effect and when reporting p-values for statistical tests 
comparing outcomes or effects between groups. 
We recommend against the use of “-fold” terminology because it can be difficult to determine 
whether it is being used to describe relative versus absolute differences or changes between 
groups or conditions. 
Whenever possible, provide an estimate of variability or precision when reporting measures of 
association or central tendency (e.g., confidence intervals, standard deviations, interquartile 
ranges), regardless of whether p-values are also reported for these estimates. 
6.1.3.  
6.1.4. Abbreviations 
 
All abbreviations, including abbreviations for elements (e.g., Fe, Cu) and chemical compounds 
[e.g., polychlorinated biphenyls (PCBs), carbon dioxide (CO2)], should be defined in the text on first 
use with abbreviations used thereafter. 
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Units of measure should be abbreviated only when a specific amount is given (e.g., “concentration 
of 10 ng/mL” versus “units of nanograms per milliliter”). 
6.1.5. In-Text Citations and Reference Lists 
 
References and citations must be formatted according to EHP style as described below. This will 
reduce copyediting time and the number of author queries included in page proofs. Authors should 
double-check all references for accuracy and completeness of information, spelling, diacritical 
marks, symbols, subscripts/superscripts, and italics. Authors are fully responsible for the accuracy 
of their references. 
 
In-Text Citations 
 
All in-text citations must be in name/date form. Place the citation immediately after the textual 
information cited, placing name and date within parentheses without a comma. EndNote is a useful 
source for EHP reference style; the current EHP reference style for EndNote can be downloaded 
from http://www.endnote.com/support/enstyles.asp. 
 Single author: (Wing 2002) 
 Two authors: (Wing and Wolf 2000) 
 Three or more authors: Use first author’s last name plus “et al.” (Wing et al. 2008) 
 Multiple sources cited at one time: List publications alphabetically by author in the citation. 
Separate publications by the same author(s) with commas and those by different authors with 
semicolons: (Aldridge et al. 2005; Jameson et al. 2006; Levin et al. 2007; Slotkin 2004a, 2004b; 
Slotkin et al. 2008) 
 Multiple sources cited at one time with different first authors but same last name and date: Use 
first author’s last name plus initial(s) (Smith A 2000; Smith J 2000). 
Provide references for any quotations used in the text. For example: 
According to Rubin et al. (2001), “it is only with a multidisciplinary and collaborative approach that 
the environmental and public health significance of Pfiesteria will be fully understood.” 
Any items that must be cited but are not accessible to the public must appear in the text in 
parentheses but should not be listed in the references: (Ramsdell JS, Moeller PDR, personal 
communication); (Reeves MK, unpublished data). 
 
Reference List 
 
Authors are fully responsible for the accuracy of their references. The list of references should 
begin on a new page after the Conclusions of the manuscript. All references must include 
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 Author/editor last name plus initials (for six or fewer authors; if there are more than six authors, 
use “et al.” after the sixth) or authoring agency 
 Year of publication 
 Full title of article or chapter (lower case) 
 Title of journal [abbreviated according to BIOSIS, Index Medicus, or PubMed 
(http://www.ncbi.nlm.nih.gov/nlmcatalog/journals)] or book/proceedings in title case 
 For books and meeting reports, city/state/country of publication and name of publisher 
 Volume and inclusive page numbers 
 DOI number, if available; this information is required for articles published online only 
 For websites and documents available online, URL (web address) and date accessed. 
If you are uncertain what to include, please include all information. 
List references alphabetically by the last name of the first author. If the first author has more than 
one publication, list references in alphabetical order (letter by letter) of subsequent authors. If the 
first author shares the last name with another first author (Smith JM vs. Smith RB), alphabetize by 
initials. If you list more than one publication by the same author/group of authors, arrange 
publications by date, early to late. If you list more than one publication published in the same year 
by the same author/group of authors, use a, b, c, and so on to distinguish the publications. 
 
Sample Alphabetical List 
 
Slotkin TA. 2004a. Cholinergic systems in brain development and disruption by neurotoxicants: 
nicotine, environmental tobacco smoke, organophosphates. Toxicol Appl Pharmacol 198:132–
151. 
Slotkin TA. 2004b. Guidelines for developmental neurotoxicity and their impact on organo-
phosphate pesticides: a personal view from an academic perspective. Neurotoxicology 25:631–
640. 
Slotkin TA. 2005. Developmental neurotoxicity of organophosphates: a case study of chlorpyrifos. 
In: Toxicity of Organophosphate and Carbamate Pesticides (Gupta RC, ed). San Diego:Elsevier 
Academic Press, 293–314. 
Slotkin TA, MacKillop EA, Ryde IT, Tate CA, Seidler FJ. 2007. Screening for developmental neuro-
toxicity using PC12 cells: comparisons of organophosphates with a carbamate, an organochlorine 
and divalent nickel. Environ Health Perspect 115:93–101. 
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Slotkin TA, Persons D, Slepetis RJ, Taylor D, Bartolome J. 1984. Control of nucleic acid and protein 
synthesis in developing brain, kidney, and heart of the neonatal rat: effects of a difluoro-
methylornithine, a specific, irreversible inhibitor of ornithine decarboxylase. Teratology 30:211–
224. 
Slotkin TA, Seidler FJ. 2007. Comparative developmental neurotoxicity of organophosphates 
in vivo: transcriptional responses of pathways for brain cell development, cell signaling, cytotoxicity 
and neurotransmitter systems. Brain Res Bull 72:232–274. 
6.1.6.  
6.1.7. Types of references 
 
Journal article—conventional reference 
Lewin SW, Arthur JR, Riemersma RA, Nicol F, Walker SW, Millar EM, et al. 2002. Selenium 
supplementation acting through the induction of thioredoxin reductase and glutathione peroxidase 
protects the human endothelial cell. Biochim Biophys Acta 1593:85–92. 
Journal article—advance publication 
Fanshawe TR, Diggle PJ, Rushton S, Sanderson R, Lurz PWW, Glinianaia SV, et al. 2007. 
Modelling spatio-temporal variation in exposure to particulate matter: a two-stage approach. 
Environmetrics; doi:10.1002/env.889 [Online 17 December 2007]. 
Journal article—published online only 
Cazelles B, Chavez M, McMichael AJ, Hales S. 2005. Nonstationary influence of El Niño on the 
synchronous dengue epidemics in Thailand. PLoS Med 2:e106; 
doi:10.1371/journal.pmed.0020106. 
Journal article, “in press” 
Theppeang K, Glass TA, Bandeen-Roche K, Todd AC, Rohde CA, Schwartz BS. In press. Sex 
and race/ethnicity differences in lead dose biomarkers: predictors of lead in blood, tibia, and patella 
in older, community-dwelling adults in an urban setting. Am J Public Health. 
Chapter in edited book 
Clark K, Cousins I, MacKay D, Yamada K. 2003. Observed concentrations in the environment. In: 
The Handbook of Environmental Chemistry, Vol 3, Part Q: Phthalate Esters (Staples CA, ed). New 
York:Springer, 125–177. 
Agency as author 
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National Research Council. 2011. Guide for the Care and Use of Laboratory Animals. 8th ed. 
Washington, DC:National Academies Press. 
Proceedings 
Zaslavsky I, Pezzoli K, Valentine D, Lin A, Sarabia H, Ellisman MH, et al. 2006. Integrating GIS 
and portal technologies for assessing environmental health impacts of Hurricane Katrina. In: 
Proceedings from the Second International Conference on Environmental Science and 
Technology, 19–22 August 2006, Houston, TX, Vol 2 (Starrett SK, Hong J, Lyon WG, eds). 
Houston, TX:American Science Press, 385–390. 
Web document 
NTP (National Toxicology Program). 2008. NTP-CERHR Monograph on the Potential Human 
Reproductive and Developmental Effects of Bisphenol A. NIH Publication no. 08-5994. Available: 
http://cerhr.niehs.nih.gov/evaluations/chemicals/bisphenol/bisphenol.pdf [accessed 24 June 
2010]. 
Website 
CDC (Centers for Disease Control and Prevention). 2013. National Health and Nutrition 
Examination Survey Homepage. Available: http://www.cdc.gov/nchs/nhanes.htm [accessed 
5 November 2013]. 
(Additional reference samples are available below.) 
6.1.8.  
6.1.9. Footnotes 
 
Do not use footnotes. Place all textual information within the manuscript and all references in the 
proper form both in text and in the reference list. 
6.1.10.  
6.1.11. Preparing Tables and Figures 
 
Tables 
Each table must begin on a new page after the References. Tables must be numbered with Arabic 
numerals, followed by a brief title (not to exceed 25 words). Tables should contain no more than 
two layers of column headings. A column heading must be provided for each column. Additional 
column heads should not be placed in the middle of a table. Tables must be created using the 
Table feature in Microsoft Word. List abbreviations and definitions under each table. Type 
footnotes directly after the abbreviations, beginning on the next line. General footnotes to tables 
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must be indicated by lowercase superscript letters beginning with “a” for each table. Footnotes 
indicating statistical significance must be identified in the following order: asterisks (*, **), number 
signs (#, ##), and daggers (†, ††). The comparison to which the p-value applies must be clearly 
indicated (e.g., “compared with untreated controls”). For presentation of data in tables, please use 
the “±” symbol for arithmetic mean and standard deviation or standard error (e.g., “mean ± SE”) 
and parentheses for the standard error when presented with the geometric mean [e.g., “GM (SE)”]. 
Please present number and percent as “n (%)” (i.e., in one column separated with one space). 
Confidence intervals should be presented in parentheses in the same column as the point 
estimate, with the upper and lower bounds separated by a comma [e.g., (0.1, 2.3)]. 
 
Figure Legends 
 
Figure legends should be provided on a new page after tables. Each figure legend should include 
a title for the entire figure and descriptors for each panel [e.g., “Figure 1. Incidence of hepatocellular 
adenomas (A) and carcinomas (B) in mice exposed to DEHP”]. Define error bars and any 
abbreviations not defined in the text. Footnotes indicating statistical significance must be identified 
in the following order: asterisks (*, **), number signs (#, ##), and daggers (†, ††). The comparison to 
which the p-value applies must be clearly indicated (e.g., “compared with controls from the 
corresponding age group”). Type footnotes directly after the abbreviations beginning on the next 
line. 
 
Figures 
 
Each figure must be provided as a separate file in one of the following formats: EPS, PDF, TIFF, 
or JPG. Do not embed figures in the main text (Microsoft Word) file. Each figure must be labeled 
with the figure number. For TIFF or JPG format, the resolution should be 300 dpi for color images, 
600 dpi for grayscale images, and 1,200 dpi for line art (black-and-white art). JPG files should be 
saved on the “highest quality” setting. Color images should be RGB and saved at a minimum of 
8 bits per channel. Because figures may be reduced or enlarged to fit our layouts, sufficient 
resolution is essential. Vector images should be saved as editable EPS files. Any images 
embedded in the EPS should also be included in a separate file. Do not convert text to path outlines 
before submission. 
Graphics must fit standard letter-size paper (8.5 × 11 inches, portrait orientation). Multiple panels 
within a figure also must fit on a single page. All letters, numbers, and lines must be clearly legible 
and easy to differentiate. Provide a key defining representational elements (e.g., dotted/dashed 
lines, symbols, box plot elements) for each figure. All axes must be clearly labeled, giving both the 
measure and the unit of measurement where applicable. Consistency among terms and styles 
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(including symbols and colors) used in figures is desirable. For example, if a black circle represents 
the control in Figure 1, a black circle (or a black bar) should be used for controls in all other figures. 
Photomicrographs should include a scale bar in each image, and the length should be specified in 
the typed figure legend (e.g., “bar = 10 µm”). EHP encourages authors to use color to enhance 
figures. However, to ensure accessibility, all figures must be interpretable when printed in black 
and white. 
 
EHP editors reserve the right to request that complex figures (e.g., figures with multiple panels 
showing information in a variety of formats, or that include panels related to different experiments) 
be divided into separate figures for publication. Questions concerning figures should be directed 
to EHPmanuscripts@niehs.nih.gov. 
 
Image Integrity 
 
Adjusting an image for brightness and contrast is acceptable if it is applied to the entire image. 
Background data of gels and blots must not be removed. The final image must accurately represent 
the original data. 
6.1.12.  
6.1.13. Supplemental Material 
 
EHP welcomes reasonable amounts of material suitable for inclusion as online documentation for 
submitted manuscripts. Examples are bioinformatic data, formulae, statistical derivations, full gene 
data and analysis, additional high-resolution microscopic data, kinetic analyses, and other 
supporting tables, figures, or videos. The submitted manuscripts must be able to stand alone in 
the absence of Supplemental Material. All information included as Supplemental Material should 
be directly relevant to the article; however, information should be included only in the paper or the 
Supplemental Material—not in both. The principal methodological approach must be clearly 
described in the main body of the paper and not relegated to Supplemental Material. Supplemental 
Material will be peer reviewed along with the manuscript and thus must meet the same rigorous 
standards. 
 
Supplemental Material should not exceed 2,000 words, including text, tables, references, and 
figure legends plus an additional 250 words per figure. If the Supplemental Material exceeds this 
limit, the author must justify the overage in the Cover Letter required at submission. Authors may 
provide a separate (permanent) web repository for information that is not included in the 
Supplemental Material file if they believe it would be of interest to readers. This material should be 
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clearly identified as not peer reviewed. This information should be cited in the text and included in 
the reference list (formatted as a website). 
Supplemental Material files are linked to papers through a common DOI number. We use 
Supplemental Material files “as is” (i.e., EHP will not copyedit or reformat the file). Therefore, please 
carefully check files to confirm that they are complete, accurate, and ready for publication. 
 Begin the Supplemental Material file with a title page that indicates “Supplemental Material” 
followed by the title of the paper and the author list. 
 Provide a Table of Contents (on or after the title page) if the Supplemental Material comprises 
multiple tables, figures, and/or sections of text. 
 Place figure legends below corresponding figures. 
 Landscape (versus portrait) layout may be used when needed. 
 Tables or figures included in the Supplemental Material should be labeled as Table S1; Figure S1; 
and so on. 
 When referring to Supplemental Material in the main manuscript, indicate the table, figure, or 
section as follows: See Supplemental Material; see Table S1; see Fig. S1; see Supplemental 
Material, p. 6; see Supplemental Material, Part 2. 
 A separate reference list must be included in the Supplemental Material file for any sources cited 
in the Supplemental Material, even if they are cited in the main paper. 
  
7. MANUSCRIPT SUBMISSION 
7.1.1.  
7.1.2. Editorial Manager 
 
Manuscripts submitted to EHP will be processed using Editorial Manager, an online manuscript 
submission and tracking program (http://www.editorialmanager.com/ehp). 
7.1.3.  
7.1.4. Initial Submission of a Manuscript 
 
Authors should either log in or select the “Create a New Account” icon to create a new account. 
To determine if an account exists, e-mail EHPmanuscripts@niehs.nih.gov. Once logged in to the 
Manuscript Central site, authors must select the “Author Center” link. From this point, the system 
will guide the user through the submission process. Online help is available at all times during the 
process via the “Get Help Now” button in the upper right corner of the screen. Users may also exit 
and reenter the submission process at any time before completing a manuscript submission. 
After completing an online submission, authors must submit a CFID form as soon as possible. This 
form can be found by selecting the “Instructions & Forms” link in the Author Center. The assigned 
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manuscript number should be noted on the form. Authors should complete and sign the form, then 
submit a scanned document by e-mail to EHPManuscripts@niehs.nih.gov. Completed forms may 
also be faxed to (301) 480-2956. 
 
Authors can monitor the progress of submissions at any time by logging in to the Author Center 
using their ID and password. Forgotten passwords may be obtained by entering your e-mail 
address in the “Password Help” section of EHP’s Manuscript Central homepage. If an account 
exists, instructions for resetting the password will be e-mailed to the user. 
Manuscripts may be submitted only via the online system. Manuscripts submitted by other methods 
(e.g., hard copy, e-mail) will not be processed. 
7.1.5.  
7.1.6. Required Cover Letter 
 
A cover letter must accompany the manuscript and include the following points: 
 Assurances that the manuscript a) is an original work, b) has not been previously published whole 
or in part, and c) is not under consideration for publication elsewhere 
 A statement that animals used in research have been treated humanely according to institutional 
guidelines, with due consideration to the alleviation of distress and discomfort. The source of those 
guidelines must be provided 
 A statement that participation of human subjects did not occur until after informed consent was 
obtained 
 Confirmation that all authors have disclosed any actual or potential competing interests regarding 
the submitted article and the nature of those interests (the required CFID form is available 
at http://ehp.niehs.nih.gov/cfi.pdf) 
 If applicable, written permission from any copyright holder (usually the publisher) to reproduce 
figures, tables, questionnaires, or a substantial block of text in both print and electronic forms 
 A statement indicating that all authors a) have read the manuscript, b) agree the work is ready for 
submission to a journal, and c) accept responsibility for the manuscript’s contents 
 The names and e-mail addresses of up to six possible preferred reviewers, as well as up to six 
nonpreferred reviewers for the manuscript 
 If applicable, a statement concerning previous publication of a manuscript or materials that might 
be considered redundant or duplicative. 
7.1.7. Peer Review 
Manuscripts are assessed for originality, scientific quality, environmental health significance, clarity 
of presentation, and conciseness. Scientific quality and environmental significance have a higher 
weight than the other criteria. 
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All new submissions undergo an initial review by a group of consulting editors. Authors will be 
notified within 1–3 weeks if their paper is not selected for peer review based on the evaluation. 
Papers selected for peer review (~ 20% of new submissions) are assigned to an Associate Editor, 
who identifies at least two peer reviewers and makes recommendations to the Editor-in-Chief 
based on their reviews. Reviewer names are not provided to authors, but author names are 
available to reviewers. Reviewers are asked to complete their review within 2 weeks. 
After editorial consideration, a decision letter and reviewers’ comments will be e-mailed to authors. 
If a revision of the manuscript is required, authors must submit the revised manuscript 
to EHP within 6 weeks of the request. If authors fail to meet this deadline, the submission will be 
canceled unless the authors have obtained prior permission for an extension from the Editor-in-
Chief. Authors must submit both the revised manuscript and a letter responding to reviewers’ 
comments. 
7.1.8.  
7.1.9. Resubmission of a Revised Manuscript 
 
If EHP requests revisions or accepts the manuscript, authors will need to submit all of the following 
through Editorial Manager (http://www.editorialmanager.com/ehp): 
 All text, tables, and figure legends must be in one Microsoft Word document. Please ensure that 
any symbols and equations appear correctly on printed copies and that all figures and tables are 
cited in the body text in numerical order. 
 Each revised figure must be submitted as a separate file in one of the following formats: EPS, PDF, 
TIFF, or JPG. Each figure must be labeled with the correct figure number for the revised 
manuscript. Additional information on formatting and content requirements is provided in 
“Preparing Tables and Figures” above. 
 Authors must submit a cover letter with point-by-point responses to the reviewers’ comments, a 
copy of the revised manuscript with changes tracked in Microsoft Word, and a clean version of the 
revised manuscript with all changes accepted. To expedite the processing of revised manuscripts, 
it is important to be as specific as possible in responding to reviewers’ comments. Authors should 
copy the editors’ and/or reviewers’ comments into the response letter and respond to each 
comment individually, including the specific changes made in response to each comment (if any) 
and where the changes are located in the revised draft. As in the original submission, the revised 
manuscripts must have numbered lines to facilitate locating specific text or changes. 
 Revised manuscripts must conform to EHP length requirements, even if additional material is 
added to the manuscript in response to reviewer requests. Authors should consult with the 
Associate Editor for their paper for additional guidance if needed. Papers that substantially 
exceed EHP word limits may be returned to authors for additional revisions to reduce their length 
before acceptance. 
120 
 
7.1.10.  
7.1.11. Final Internal Review 
 
All manuscripts undergo an in-house editorial review of scientific content and accuracy as well as 
compliance with EHP formatting and Competing Financial Interests requirements before they are 
accepted for publication. Authors will be notified that their paper has been accepted provisionally, 
at which point they may be asked to respond to additional post-review requests from 
the EHP Editor-in-Chief or Science Editor. Authors also are asked at this point to conduct their own 
final review of their paper to confirm that it is ready for Advance Publication. Authors should be 
aware that on rare occasions this final review identifies serious concerns that might prevent 
acceptance. However, in most cases, final acceptance will occur after authors respond to requests 
or questions raised by the final review. 
  
8. PUBLICATION SEQUENCE 
8.1.1.  
8.1.2. Advance Publication 
 
EHP publishes unedited PDF versions of articles online as Advance Publication articles 
(http://www.ehponline.org/) within 3 working days of final acceptance unless a prepublication 
embargo period is agreed upon in advance (for more information on embargoes, see “Press 
Releases and Embargo Policy” below). In addition, unedited abstracts are published online in 
PubMed (http://www.ncbi.nlm.nih.gov/pubmed/) and at http://www.ehponline.org/. The date the 
Advance Publication article is posted on the website will be considered the publication date of 
record. 
 
Advance Publication articles are citable using the assigned DOI (Digital Object Identifier) number 
for the article. The DOI number enables the article to be immediately referenced and establishes 
publication priority. Papers are not copyedited until they are prepared for final publication. The PDF 
version of Advance Publication articles will be replaced with the copyedited, formatted version as 
soon as possible, and the DOI number will carry over to the copyedited article. In addition to the 
DOI number, the copyedited article will include assigned volume and page numbers that will allow 
full conventional citation. 
8.1.3.  
8.1.4. Copyediting/Page Proofs 
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To prepare each paper for final publication, EHP staff will convert electronic material to a desktop 
publishing format and copyedit the manuscript. The copyedited version, with embedded author 
queries, will be converted to PDF page proofs and sent to authors by e-mail. The authors can use 
free Acrobat Reader software (http://get.adobe.com/reader/otherversions/) to review the proofs. 
There are two methods of correcting and returning proofs: 
 Authors may use Comment and Markup Tools in Acrobat and e-mail the corrected proof to the 
responsible editor. 
 Authors may print the proof and write corrections directly on the printed copy, and then scan the 
marked proof and return it by e-mail. Authors using this method should also include with the page 
proofs a list of itemized changes (including their locations). 
The copyedited proofs of an article may be slightly different from the Advance Publication version 
as a result of the editing process, but no substantive changes will be allowed. Any significant 
changes at this stage of processing will require a correction to be published at the end of the article. 
Extensive changes cannot be made at the proof stage; only minor changes, such as spelling, 
grammar, clarification, and referencing, should be requested. If new information has become 
available after acceptance of the manuscript, an addendum in proof can be included with the 
permission of the Editor-in-Chief. 
Should a change to the author lineup be requested (add or remove an author, or change the order 
of authors), EHP must receive written approval from all authors indicating that they approve the 
change before it can be executed. This approval can be provided as a signature (in ink and 
scanned) or as a direct email to EHP; either approval method must include a copy of the new 
lineup. It is the corresponding author’s responsibility to coordinate co-author approvals of the new 
lineup. Approvals on behalf of an author will not be accepted. Your paper will remain on hold until 
all approvals are received, so a request to change the author lineup could result in a delay to your 
publication date. Should all authors fail to approve the lineup, EHPwill either publish the paper with 
the old lineup, or will consider retracting the article at the request of the authors. 
8.1.5.  
8.1.6. Copyright, Reproduction, and Citation 
 
EHP is a publication of the U.S. Government. Publication of EHP lies in the public domain and is 
therefore without copyright. All text from EHP may be reprinted freely. Use of materials published 
in EHP should be acknowledged (for example, “Reproduced with permission from Environmental 
Health Perspectives”); pertinent reference information should be provided for the article from which 
the material was reproduced. Articles from EHP, especially the News section, may contain 
photographs or figures copyrighted by other commercial organizations or individuals that may not 
be used without obtaining prior approval from the holder of the copyright. For further information, 
contact EHP Permissions (ehponline@niehs.nih.gov). 
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8.1.7.  
8.1.8. Press Releases and Embargo Policy 
 
Authors are responsible for arranging media outreach with their own press offices in conjunction 
with EHP. EHP will schedule publication dates to suit the needs of authors and their press officers. 
We recommend an embargo period of at least 2 full working days for any paper that receives a 
press release. This gives members of the media time to prepare stories and contact corresponding 
authors for additional information. 
 
Authors whose papers have been provisionally accepted for publication should contact Susan 
Booker, EHP News Editor, at booker@niehs.nih.gov to coordinate embargo and publication dates. 
Authors or press officers should also provide EHP a copy of their final press release. 
Upon final acceptance EHP will send press officers a PDF copy of the Advance Publication version 
of the article to be distributed to media who request it. All pre-press materials will be clearly 
identified as embargoed and will include the embargo date and time established by EHP in 
conjunction with the authors. Authors must adhere to EHP’s embargo policy, and authors and 
media alike are responsible for ensuring that all third parties with whom they share pre-press 
materials honor the embargo. 
 
 
 
 
 
